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Introduction- Cardiovascular complications contribute dramatically to morbidity and 
mortality incidence amongst individuals who have developed type 2 diabetes (T2D), with 
myocardial insulin resistance (IR) playing an important role. Poor lifestyle choices and 
dietary habits such as increased sugar-sweetened beverage (SSB) consumption have 
emerged as key contributors to the global ‘epidemic’ of obesity, diabetes and heart 
disease. However, the underlying mechanisms whereby SSBs drive the onset of cardio-
metabolic complications remain unclear. For the current study, we hypothesized that 
long-term SSB consumption will trigger downstream glucose metabolic pathways with 
physiologically damaging outcomes. Specifically we proposed that increased glucose 
availability (due to SSB consumption) activates non-oxidative glucose pathways 
(NOGPs), i.e. polyol pathway, hexosamine biosynthetic pathway (HBP), advanced 
glycation end-products (AGE), and PKC activation that may in turn contribute to cardio-
metabolic complications. 
 
Methodology- Male Wistar rats (200 g) were gavaged daily with 3-5.1 mL of well-
known, local SSBs and ASBs for a total period of six months. Dietary behavior and 
phenotypic changes were monitored on a weekly basis, while systemic (fasted) 
triglyceride, cholesterol and glucose levels at various time points during the study period. 
Furthermore, we performed oral glucose tolerance tests (OGTTs) biweekly, and also 
determined overall weight gain and organ tissue mass. Myocardial NOGPs were 
evaluated using commercially available kits and by Western blotting techniques.  
 
Results- Our data reveal that after six months the different soda groups displayed 
minimal macroscopic changes, therefore possibly representing a relatively early stage in 
terms of SSB-mediated cardio-metabolic complications. However, we also found several 
changes at the biochemical level but with distinct signatures for the Jive
®
 group compared 
to the Coca Cola
®
 and Coke Light
®
 groups. Here Jive
®
 consumption for six months 
resulted in early signs of cardiac and skeletal muscle hypertrophy, together with increased 
liver mass and perturbed adipocyte ultrastructure. We also established that the majority of 
the myocardial NOGPs were activated that may have contributed to some of the changes 
already found and that may lead to the onset of future complications. The Coca Cola
®
 and 





 groups exhibited alterations in liver mass and altered adipocyte 
ultrastructure together with lower glucose clearance after six months suggesting onset of 
IR. These data also clearly show that the HBP may be a universal pathway that was 
activated in all of the soda groups, with potential long-term detrimental physiological 
effects. 
 
Conclusion- This study managed to successfully establish a novel in vivo rat model of 
chronic SSB and artificially sweetened beverage (ASB) consumption. We demonstrated 
that SSB consumption resulted in minimal macroscopic alterations but that it did trigger 
variable postprandial excursions together with the induction of several myocardial 
NOGPs.  Thus the current study shows that long-term SSB intake activates potentially 
detrimental metabolic pathways that may place organisms at risk of developing cardio-
metabolic complications despite an apparently “healthy” phenotype. 
  





Inleiding- Kardiovaskulêre komplikasies is verantwoordelik vir die bydrae tot morbiditeit 
en mortaliteit onder individue wat tipe 2 Diabetes ontwikkel het, waar miokardiale 
insulien weerstanigheid (IW) ‘n belangrike rol speel. Swak lewenstylkeuses en 
dieetgewoontes soos byvoorbeeld verhoogde suikerversoete drankies (SVDs) inname ‘n 
‘n sleutel bydraende faktor vir die wêreld epidemie, vetsugtugheid, Diabetes en 
hartsiektes. Die onderliggende meganismes waarby SVDs die aanvang van kardio-
metaboliese komplikasies aandryf bly steeds onduidelik. Vir die huidige studie is ons 
hipotese dat langtermyn SVD inname, afstroom glukose metaboliese weë met fisiologies-
skadelike effekte sal ontlok met ongewensde uitkomste. Ons stel spesifiek voor dat die 
verhoogde glukose beskikbaarheid (a.g.v. SVD inname) die nie-oksidatiewe glukose weë 
(NOGW) aktiveer, i.e. poliolweg, heksosamienbiosintetiese weg (HBP), gevorderde 
glukeringseindprodukte (GGE), en PKC aktivering wat op sy beurt tot kardiometaboliese 
komplikasies bydra. 
 
Metodologie – Manlike Wistar rotte (200 g) is daagliks met 3-5.1 mL van ‘n bekende 
lokale SVD vir ‘n periode van ses maande deur middel van orale toegediening gevoed. 
Ons het dieetgedrag en fenotipiese veranderinge gemonitor op ‘n weeklikse basis en ook 
sistemiese (vastende) trigliseried, cholesterol en glukose vlakke op verskeie tydspunte 
gedurende die ses maande toetsperiode gemonitor. Verder het ons ‘n orale glukose 
toleransie toets (OGTT) twee-weekliks uitgevoer en ook die algehele gewigstoename en 
orgaanweefselmassa gemonitor. Miokardiale NOGWs is met behulp van kommersiëel 
beskikbare toetse en deur middel van Westerse blottegnieke bepaal.  
 
Resultate – Ons data het na ses maande aangedui dat daar minimale makroskopiese 
veranderinge tussen die verskillende soda groepe waargeneem is. Dit kan ‘n relatiewe 
vroeë stadium, in terme van SSB-gemediëerde kardiometaboliese komplikasies is.  
Verder het ons verskeie biochemiese veranderinge waargeneem met uitsluitlike kenmerke 
vir die Jive
®
 groep vergeleke met die Coca Cola
®
 en Coke Light
®
 groepe. Hier het Jive
®
 
gebruik vir ses maande in vroeë tekens van kardiale en skeletspierhipertrofie gelei – 
tesame met verhoogde lewermassa en versteurde adiposietultrastruktuur. Ons het ook 
vasgestel dat die meerderheid van die miokardiale NOGWs geaktiveer was en dat dit mag 
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bydra tot die veranderinge wat reeds gevind is met die aanvang van toekomstige 
komplikasies. Die Coca Cola
®
 en Coke Light
®
 groepe het wysigings in lewermassa en 
adiposietultrastruktuur getoon met laer glukose opruiming na ses maande wat moontlik 
die aanvang van insulienweerstandigheid kan voorstel. Hierdie data toon duidelik aan dat 
die HBP ‘n unversiele weg is wat geaktiveer word in al die soda groepe, met potensiële 
langtermyn newe effekte. 
 
Gevolgtrekking – Hierdie studie het daarin geslaag om ‘n sukesvolle nuwe in vivo rot 
model van ‘n chroniese SSB/ASB inname te vestig. Ons het ook bevind dat die SSB 
inname ‘n minimale makroskopiese wysigings teweeg bring en dat dit verskeie post 
prandiale veranderinge tesame met die induksie van verskeie miokardiale NOGWs tot 
gevolg bring. Dus, het die huidige studie getoon dat langtermyn SSB inname potensiëel 
skadelike metaboliese weë aktiveer en dat dit individue met verhoogde risiko vir 
kardiovaskulêre komplikasiese verhoog ten spyte van ‘n gesonde fenotipe. 
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1.1 Defining Diabetes 
 
The term Diabetes Mellitus describes a metabolic disorder with numerous defects 
characterized by chronic hyperglycemia and the disturbances of carbohydrate, fat and protein 
metabolism, thus resulting in impaired insulin secretion and/or action. Diabetes may be 
classified into two categories, i.e. Type 1 Diabetes - the inability to produce little or no 
insulin which is usually genetically inherited; and Type 2 Diabetes (T2D) - the ability to 
produce insulin but  with a lack of insulin effects (due to insulin resistance and/or β-cell 
dysfunction) that  is often accompanied by obesity and poor lifestyle choices (Alberti and 
Zimmet, 1998). Persons can be placed into three groups with regards to Diabetes 
classifications: 1) non-diabetic, 2) pre-diabetic (impaired glucose tolerance [IGT] or impaired 
fasting glucose) and 3) diabetic. Each category has its own range of glycemic levels used in 
order to classify individuals with different stages of Diabetes (The Diabetes Forum, [s.a.]) as 
shown in Table 1.1.  
 
Each stage of Diabetes also comes with a broad range of pathogenic complications. Such 
complications typically include long-term damage, dysfunction and failure of various organs 
as well as progressive development of distinct tissue-related complications. For example, 
individuals with Diabetes are at an increased risk of developing cardiovascular, peripheral 
vascular and cerebrovascular diseases. Several pathogenic processes are involved in the onset 
of Diabetes; these include processes that damage pancreatic β-cells with the eventual onset of 
insulin deficiency, while others can result in resistance of target cells to insulin action. The 
abnormalities of carbohydrate, fat and protein metabolism are due to deficient action(s) of 
insulin on target tissues resulting from insensitivity or lack of insulin (Alberti and Zimmet, 










1.2 Global Diabetes prevalence 
 
T2D is recognized as a public health pandemic with the rise in incidence becoming more 
alarming than predicted (Boyle et al., 2001). According to the World Health Organization 
(WHO) the prevalence for persons living with Diabetes has shifted from 135 million in 
1998 to 171 million in the year 2000; with estimates indicating that this number will 
continue to rise to 366 million by 2030 (Bradshaw et al., 2007) - Figure1.1 indicates the 
prevalence of Diabetes worldwide and the predicted values for 2030. The reasons for this are 
multi-factorial but key drivers for the increased prevalence include growing populations, 
urbanization and most importantly an increase in physical inactivity together with the 
increased consumption of unhealthy diets (Wild et al., 2004). This rising prevalence is in turn 
a central contributor to morbidity and premature mortality, both in developed and developing 






2 hours after meals 
(postprandial) 
Non-diabetic 4.0 to 5.9 mmol/L under 7.8 mmol/L 
Pre-diabetic 6.0 to 6.9 mmol/L under 7.9 to 11.1 mmol/L 
Type 1 Diabetes > 7 mmol/L under 9 mmol/L 
Type 2 Diabetes > 7 mmol/L under 8.5 mmol/L 
Table 1.1: Values for diagnosing Diabetes Mellitus and other classes of hyperglycemia 
(adapted from: The Diabetes Forum, [s.a.], adapted from The International Diabetes 
Federation [IDF]). 




Figure 1.1: A schematic representation of the diabetic prevalence in 2000 and the predicted values for 2030 worldwide. 
Numbers are presented in millions and calculated percentages are included (Hossain et al., 2007). 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
4 
 
1.3 Diabetes in developing nations  
 
As developing countries grow and their economies expand, non-communicable diseases such 
as Diabetes will become more prevalent largely because of the adoption of a so-called 
‘Western’ lifestyle and its accompanying risk factors (Wild et al., 2004). As discussed, most 
of the increase in Diabetes prevalence will occur in developing countries that are also 
strongly linked with growing urbanization (Bradshaw et al., 2007; Guariguata et al., 2014). 
Such countries fall within the following continents; Asia, some countries in Europe, South 
America and sub-Saharan Africa (discussed by Prentice, 2006). Although Diabetes Mellitus 
was initially considered to be rare in sub-Saharan Africa this has dramatically changed with it 
now emerging as a significant medical concern within such a developing continent (Motala et 
al., 2003).  
 
The burden of T2D in South Africa (SA) is excessively high compared to the rest of the 
African continent, with the prevalence expected to rise to ~ 1.6 million by 2030 (Shaw et al., 
2010). Furthermore, Diabetes is the seventh most common cause of mortality in SA and 
several studies suggest that high blood glucose levels can increase cardiovascular mortalities 
and thus further fuel the overall burden of disease. This increase in diabetic incidence in the 
SA population is closely linked with urbanization together with sedentary lifestyle choices 
and unhealthy dietary behavior (Bradshaw et al., 2007). Here T2D is also closely associated 
with obesity (poor lifestyle and genetic influences) and cardiovascular complications. 
Alarmingly, the number of obese individuals has increased in relatively “health conscious’’ 
nations , therefore making it one of the most important contributors to T2D onset (Seidell, 
2000). 
 
1.4 The associated risk factors of Diabetes 
 
“Obesity has emerged as one of the greatest health challenges of the 21
st
 century” (Caprio, 
2012). Worldwide obesity is fast becoming a problem of epidemic proportions and with it 
increasing risks of premature death. For example, the WHO estimated that 700 million 
persons will be obese by the year 2015 (Malik et al., 2010) and this will increase the risk of 
developing T2D and cardiovascular disorders. Intriguingly, such risks may in some cases 
present in individuals with normal body mass index (BMI) ranges (Van Gaal et al., 2006). 
Studies have described an inverse relationship between obesity and heart failure which is 
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referred to as the ‘obesity-mortality paradox’ (Ahima and Lazar, 2013). For example, studies 
done by Flegal et al. (2013b) showed that obesity alone was not associated with higher 
mortality compared to normal weight (BMI 18 to less than 25 kg/m
2
) individuals.  
 
Obesity can manifest as a result of a variety of factors, e.g. physical inactivity, inadequate 
nutrient intake, sedentary lifestyles, as well as genetic factors. Obese individuals are at an 
increased risk for developing T2D and related cardiovascular diseases (CVD). Insulin 
resistance (IR) has emerged as an important mechanism that may play a role in the 
development of such conditions.  
 
IR can be defined as a condition where the body is unable to respond to physiological 
concentrations of insulin resulting in impaired glucose utilization. Obesity itself also 
exacerbates the degree of IR and these factors are associated with cardiovascular risk factors 
such as hypertension, dyslipidemia and development of the metabolic syndrome (leads to the 
development of T2D and CVD). For cardiovascular tissues, IR can have a multi-faceted 
effect and lead to the inhibition of a variety of metabolic pathways which can further 
decrease glucose uptake and ultimately impede normal cardiac function (Van Gaal et al., 
2006).  
 
Obesity and IR can contribute to progressive damage to the vasculature and result in 
endothelial dysfunction (Caballero, 2003). Endothelial dysfunction can be described as partial 
or complete loss of stability between vasodilators and vasoconstrictors (Caballero, 2003); 
therefore, endothelial dysfunction may contribute to the development of contractile 
dysfunction and micro-vascular complications in Diabetes. One of the proposed mechanisms 
linking obesity and IR is the pathogenic effect of oxidative stress and subsequent endothelial 
dysfunction (Van Gaal et al., 2006). However, such mechanisms are complex and pathways 
often cross-talk between each other. The collaborate effects of such risk factors (IR, obesity 
and T2D) play a role in the onset of CVD (Figure 1.2). It is important to note that many 
factors play a role in developing CVD i.e. genetics, therefore, Figure 1.2 is a simplified 
schematic representation of disease onset. 
 
  












In 2005, the WHO estimated that there will be ~20 million CVD deaths in 2015, accounting 
for 30% of all mortalities worldwide. Researchers have projected that by 2030 non-
communicable diseases will constitute for more than three-quarters of deaths worldwide. 
Here CVD alone will be responsible for more deaths in developing countries than infectious 
diseases, including HIV/AIDS and tuberculosis (WHO, 2005). Thus, CVD is the leading 
contributor to global mortality - Figure 1.3 alerts to the number of global mortalities due to 
CVD (WHO, 2008). CVD onset can be attributed to a multitude of factors that generally 
overlap with what was discussed so far in this chapter. One of these factors includes 
urbanization or ‘Westernization’ which will now be discussed in more detail. 
  
Poor dietary habits 
 & sedentary lifestyle 
Obesity 
Diabetes 
Insulin resistance Cardiovascular 
diseases 
Figure 1.2: A schematic representation of cross-talk between complex mechanisms leading 
to CVD onset. 




Figure 1.3: The total number of deaths due to CVD worldwide (WHO, 2008).  
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1.5 The ‘Western’ influence on Diabetes 
 
T2D and obesity arise from related lifestyle-dependent risk factors, including poor dietary 
habits and lack of physical activity. Furthermore, with increased urbanization these risk 
factors are becoming more common in developing nations (Danaei et al., 2013). Dietary 
behavior and specific food content (such as sugar-sweetened beverages [SSB]) are associated 
with CVD and T2D with detrimental outcomes, for example, hypertension, obesity, 
hyperglycemia and insulin resistance (He et al., 2013; Mozaffarian et al., 2011; Sacks et al., 
2009). 
 
Investigating dietary patterns and food consumption offers an added dimension where one 
can assess the relationship between dietary behavior and disease risk/development (Fung et 
al., 2001). For example, in recent times more individuals are ingesting increased amounts of 
fats and refined carbohydrates that typically accompany decreased physical activity to 
constitute the more commonly referred to ‘Western’ diet or lifestyle. This shift in dietary 
behavior is not only observed in developed countries, but is rapidly becoming more frequent 
in developing nations (Popkin, 2001). The so-called ‘Western’ diet is also closely linked to 
higher caloric intake by increased SSB consumption (the focus of this research project) (Fung 
et al., 2001; Welsh et al., 2011).  
 
1.6 Sugar-sweetened beverages in the Western diet  
 
1.6.1 Classification of sugar-sweetened beverages 
 
Soda beverages can be classified into two categories, i.e. caloric sweeteners which include 
sucrose- and fructose-sweetened beverages (SSBs), and non-caloric sweetened beverages 
which include those that are sweetened with artificial sweeteners (ASB) such as aspartame 
(Bray et al., 2004). Several studies have been conducted in order to elucidate the effects of 
these beverages on the body, which will be discussed in more detail below. 
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1.6.2 The effects of consuming sugar-sweetened beverages 
 
There has been a sharp increase in the global consumption of caloric beverages in the last few 
decades (Brownell et al., 2009). Numerous adverse effects and disease risk factors arise due 
to SSB consumption (De Ruyter et al., 2012) as the body does not compensate for the excess 
calories consumed. Here detrimental outcomes may include weight gain, fatty liver disease, 
T2D and cardio-metabolic changes (De Ruyter et al., 2012; Popkin, 2012). In addition, SSB 
intake may not trigger the satiety response and this may be an important link between 
elevated liquid calories and increased health risk. Studies have linked the ingestion of SSBs 
to numerous risk factors which may lead to the development of CVD. These factors include 
increased visceral deposition, elevated triglyceride and cholesterol metabolites, and an 
increase in body weight (or BMI) (De Ruyter et al., 2012; Ebbeling et al., 2012; Malik et al., 
2010). 
 
One of the world’s most popular SSBs is Coca Cola
®
. Here the main ingredient present is 
high fructose corn syrup (HFCS) which is made up of ~50% sucrose and ~50% fructose. In 
addition, the majority of processed foods also contain HFCS as a main ingredient. As HFCS 
is much sweeter than table sugar, this constitutes a major reason for its popularity within the 
food industry (Raatz et al., 2014). Fructose and glucose not only differs in taste but is also 
absorbed differently in the gastrointestinal tract. 
 
Both glucose and fructose are absorbed in the small intestine, however, glucose is taken up 
through GLUT 4 transporters and fructose trough GLUT 5 transporters. Fructose does not 
induce the same insulin response as glucose due to there being very little GLUT 5 
transporters in the pancreas (Johnson et al., 2013).  
 
Evidence suggests that fructose may be a key factor at play with high SSB intake. It is found 
in approximately equal amounts in corn syrup compared to sucrose and other sugar forms that 
are present in SSBs. In fact, fructose alone elicited detrimental effects on blood pressure, 
visceral fat deposition, weight gain and IR (Caprio, 2012; Popkin, 2012). The mechanisms 
that contribute to the associated risk factors for IR, obesity and T2D may include an 
incomplete reduction in energy intake after consumption of SSBs and glycemic effects with 
rapid spikes in blood glucose levels (hyperglycemia) and insulin concentrations (Fagherazzi 
et al., 2013; Qi et al., 2012).  
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Although few studies have investigated the relationship between SSB consumption and the 
onset of associated diseases, the evidence suggests a link between SSBs and weight gain, 
CVD and T2D (Qi et al., 2012) (refer to Figure 1.4). The consumption of various 
carbohydrate forms (sugars and HFCS) contribute to high dietary glycemic load, 
inflammation and IR- irrespective of obesity (Ludwig, 2002). Moreover, the consumption of 
both SSBs and ASBs lead to a dramatic increase in blood glucose and insulin concentrations 
(Anton et al., 2010; Fagherazzi et al., 2013; Malik et al., 2010), that can directly impede 
hepatic insulin signaling and thereby promote IR (Swarbrick et al., 2008). However, despite 
advances in this field there is - to our knowledge - no clear molecular mechanisms that have 
been proposed to describe the association between the consumption of SSB, increased 








Figure 1.4: The risk evaluation of developing Type 2 Diabetes with the consumption of 
sugary-sweetened beverages, artificially sweetened beverages and fruit juices.  
Solid lines correspond to hazard ratios (HR) and the dotted lines correlate to the 95% 
confidence intervals (CI) (adapted from Fagherazzi et al., 2013). 
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1.7 Problem statement 
 
To summarize, metabolic dysfunction triggered by SSB consumption plays an important role 
in causing various lifestyle diseases and thus contributing to the overall health care burden 
(morbidity and mortality). However, the underlying molecular mechanisms are poorly 
understood and require urgent investigation.  
 
With developing countries such as SA becoming increasingly ‘Westernized’, there is already 
evidence of greater manifestation of obesity and associated complications such as T2D and 
CVD. As discussed, this rise can be attributed to sedentary lifestyles, poor dietary habits and 
increased caloric intake from SSBs. This study was therefore initiated to begin to explore this 
intriguing question in order to gain novel mechanistic insights. Our laboratory proposes that 
acute hyperglycemic episodes may be present with the early onset of Diabetes or as a result 
of high glycemic dietary intake (Joseph et al., 2014). For this study, we propose that 
hyperglycemic episodes due to SSB intake will elicit downstream effects that will lead to the 
perturbation of specific metabolic pathways (of non-oxidative glucose metabolism) in the 
heart. We employed a novel approach to assess such mechanisms by establishing – for the 
first time as far as we are aware - an in vivo rat model of long-term SSB consumption.  
 
This chapter summarized the global pandemic of T2D and CVD with specific focus on the 
consumption of SSBs in developing countries. Chapter 2 will deal with cardio-metabolism 
under normal physiological conditions, and thereafter Chapter 3 with focus on metabolic 
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Mortality from cardiovascular complications is a common outcome for persons living with 
Diabetes. As Diabetes is a multifaceted disease, many factors play a role in its progression to 
cardiovascular complications such as heart failure and diabetic cardiomyopathy (Chavali et 
al., 2013). As outlined in Chapter 1, a number of detrimental consequences arise from poor 
lifestyle choices, therefore, confirming a robust link between metabolic perturbations and 
cardiac abnormalities. It is thus essential to understand the driving mechanisms which 
mediate the dysregulation of glycolysis in a hyperglycemic setting. 
 
The surge in inactivity, poor lifestyle choices and greater liquid calorie consumption has 
added to the incidence of hyperglycemia (e.g. by increased postprandial spikes) (Fagherazzi 
et al., 2013). However, the role of SSBs and its effects on hyperglycemia remain poorly 
understood (Ludwig, 2002). Our laboratory’s focus has been on hyperglycemia-mediated 
metabolic alterations and its role in the onset of cardio-metabolic complications (Joseph et 
al., 2014; Mapanga et al., 2012). For the current study we aimed to extend this hypothesis 
and our proposal is that hyperglycemia will be relevant within the context of chronic SSB 
consumption. In broad terms, the central hypothesis suggests that hyperglycemia is associated 
with the formation of reactive oxygen species (ROS) which play a central role in cardiac-
metabolic derangements (Brownlee, 2005; Rubin et al., 2012). Such oxidative stress is linked 
with disrupted metabolic flux through the glycolytic pathway, that may increase flux through 
non-oxidative glucose pathways (NOGPs), thus leading to harmful vascular complications 
that are typically associated with Diabetes (Brownlee, 2005; Giaccari et al., 2009). However, 
these ideas have largely centered on chronically elevated hyperglycemia, whereas our 
laboratory’s recent work focused on changes observed with short-term/acute hyperglycemia 
(Joseph et al., 2014)- interestingly, this hypothesis (that hyperglycemia leads to metabolic 
perturbations in the myocardium) remains true for both these conditions. 
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The focus of this study is therefore to investigate the overall effects of SSB consumption by 
establishing a novel in vivo rat model, with emphasis on the activation of NOGPs. Such 
research should therefore – in the longer term - provide more insight into mechanisms driving 




2.2.1 Fuel substrates 
 
As the heart has to nourish the entire body via the circulatory system, it has high energy 
demands to maintain contractile function and general homeostasis. The major energy 
production site of the heart is the mitochondrial electron transport chain (ETC) which 
generates adenosine triphosphate (ATP), the chemical energy source of myocardial cells. 
ATP can be generated by oxidative phosphorylation in the mitochondrial tricarboxylic acid 
(TCA) cycle. Here, energy inputs to drive mitochondrial oxidative phosphorylation are 
provided by transferred electrons from carbon-based fuel sources which generate reducing-
equivalents, nicotinamide adenine dinucleotide reduced (NADH) and flavin adenine 
dinucleotide reduced (FADH2). Both glucose and fatty acids (FAs) provide energy inputs in 
the form of reducing equivalents, although FA β-oxidation is the main fuel source of the 
normal mammalian heart (Stanley et al., 2005).  
 
Under normal physiological conditions, the adult heart uses FA as its major fuel substrate i.e. 
approximately 60-90% of acetyl-CoA is formed as a result of FA β-oxidation and ~10-40% 
from pyruvate oxidation (via glycolysis). High FA oxidation rates inhibit glucose oxidation in 
the heart (reviewed by Fillmore and Lopaschuk, 2011; Gertz et al., 1988). The mechanism 
through which FA regulate/inhibits glucose utilization is referred to as the Randle cycle. This 
reaction occurs because the initial event, triggered by fatty acid oxidation, is an increase in 
the mitochondrial ratios of [acetyl-CoA]/[CoA] and [NADH]/[NAD
+
], both of which inhibit 
pyruvate dehydrogenase (PDH) activity (a key enzyme which converts pyruvate into acetyl-
CoA within the mitochondrion). Under these conditions, part of the glucose that is not 
oxidized is re-routed to glycogen formation (reviewed by Hue and Taegtmeyer, 2009) (refer 
to Figure 2.1).  
 
 





























Figure 2.1: A schematic representation of the production of ATP in the myocardium. 1- Fatty 
acids are the main substrates utilized. 2- The production of fatty acyl-CoA inhibits the action 
of PDH in mitochondria. 3- With higher glucose availability (e.g. postprandially) it is utilized 
as the main fuel substrate. 4 and 5- With high FA availability, DAG can activate PKC, which 
reacts with insulin signaling subsequently interfering with GLUT4 membrane recruitment 
and increasing intracellular glucose concentrations.  
Abbreviations: Glucose transporter four (GLUT4), fatty acid translocase (FAT), adenosine 
triphosphate (ATP), tricarboxylic acid cycle (TCA), electron transport chain (ETC) and 
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FA can indirectly decrease the uptake of glucose by acting on the insulin signaling pathway. 
This occurs when FA enter into the cell and form diacylglycerol (DAG) and ceramides. DAG 
allows for the activation of PKC (which will be discussed later), which subsequently 
interferes with the insulin signaling pathway. The mechanisms behind this remain unclear, 
however, correlations have been made between decreased insulin activity and the activation 
of insulin receptor substrate (IRS) -associated phosphatidylinositol-3-OH kinase (PI(3)K) 
when PKC activity was elevated (Montell et al., 2001; Saltiel and Kahn, 2001). Although FA 
are the main fuel source of the normal mammalian heart, this may change according to 
circumstances, e.g. under hyperglycemic conditions when substrate utilization is altered.  
Thus glucose can become a major fuel substrate of the heart following a meal when its 
circulating levels robustly increase. In this instance, the myocardium is exposed to higher 
glucose availability (in circulation) and hence there is greater glucose uptake and increased 
utilization that is used to fuel ATP production (Bertrand et al., 2008).  
 
The TCA cycle is fuelled by acetyl-CoA that may be derived from pyruvate decarboxylation 
and/or from FA β-oxidation. The latter results in the formation of reducing equivalents used 
for oxidative phosphorylation in the ETC. The TCA cycle can thus be considered to be the 
main mediator in cardiac energy supplies. As discussed, the heart can also alter fuel sources 
depending on substrate availability, oxidation rates and energy demands (Atkinson et al., 
2002; King et al., 2005).  Such alterations in the balance between FA and carbohydrates as 
energy sources can contribute to differing cardiac efficiency in producing ATP (Fillmore and 
Lopaschuk., 2011); e.g. greater glycolysis may serve as a cardio-protective mechanism 
during ischemia (versus increased FA utilization) since higher FA utilization can cause 
mitochondrial uncoupling and hence a loss of ATP production (Essop, 2007). An indirect 
result is decreased myocardial utilization of glucose and decreased protective glycolysis – 
due to the Randle cycle. Therefore, switching from FA to increased glycolysis during 
ischemic events may aid the heart as it can generate ATP in a more oxygen-efficient manner 
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2.2.2 Glucose utilization 
 
The major sources of glycolytic substrates are exogenous glucose and endogenous glycogen 
stores. Glycolysis can be stimulated by adrenergic stimulation, exercise and depleted ATP 
levels in the myocardium. Although glycogen has a high turnover rate, its availability is 
relatively small in the heart when compared to skeletal muscle (Hue et al., 1995; Stanley et 
al., 1992). Dietary carbohydrates therefore contribute largely to glucose availability in the 
myocardium – especially postprandially. Upon entry into the cell, glucose is rapidly 
converted to glucose-6-phosphate, which can then enter the glycolytic pathway. This 
phosphorylation is catalyzed by hexokinase-2 that effectively traps glucose-6-phosphate in 
the cell as it cannot penetrate the sarcolemma (Bouché et al., 2004). A series of 
phosphorylation and cleavage steps thereafter convert glucose-6-phosphate to pyruvate. An 
important glycolytic enzyme in the context of high glucose availability is glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) that will be discussed in further detail in Chapter 3. Net 
flux through glycolysis contributes to ~10% of the myocardial ATP production (Opie and 
Knuuti, 2009). 
 
When pyruvate enters the mitochondrial matrix it is decarboxylated to form acetyl-CoA - 
PDH then converts pyruvate (irreversibly) to acetyl-CoA. Thus, the PDH complex is a vital 
mediator in glucose metabolism which couples glycolysis to oxidative phosphorylation 
(Randle, 1986; Vincent et al., 2004). PDH is regulated via many mechanisms, however, its 
regulation through increased FA oxidation inhibits glucose metabolism, as shown above in 
Figure 2.1 (Panchal et al., 2000). FAs lead to the inactivation of PDH which in turn increases 
citrate concentrations. This inhibits phosphofructokinase which is a key regulator in 
glycolysis. Therefore, intracellular glucose concentrations increases, resulting in decreased 
glucose uptake which may subsequently lead to IR (Shulman, 2000). When glycolytic flux 
increases the TCA cycle does so in parallel fashion, i.e. during hyperglycemic events flux is 
increased through the TCA cycle, as next discussed in further detail. 
 
2.2.3 Tricarboxylic acid cycle and electron transport chain 
 
Mitochondria are the “powerhouses” of the cell as it is the major site of ATP production. 
Cardiomyocytes are enriched with mitochondria to maintain its ATP requirements (Dobson 
and Himmelreich, 2002). After acetyl-CoA (from FA β–oxidation and glycolysis) is 
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converted to reducing equivalents, the latter is employed to produce ATP (Kavazis et al., 
2009). The major products formed in the TCA cycle include NADH and FADH2 which are 
used as electron donors to form ATP in the ETC (Gibala et al., 2000). NADH and FADH2 
can therefore be described as the link between the breakdown of fuel substrates and the 
conversion of this fuel into energy. Reducing equivalents generated by the TCA next move 
into the ETC where it is utilized for energy production. 
 
The ETC is a complex composition of proteins located within the inner membrane of 
mitochondria - which includes complexes I, II, III, IV and ATP synthase (complex V). Such 
complexes transfer electrons from NADH and FADH2 to oxygen during the formation of 
ATP (Cecchini, 2003). Between complex II and III there is a mobile electron carrier, 
coenzyme Q or ubiquinone (Co-Q), which donates electrons to oxygen thus producing 
superoxide (O2•). This step plays a vital role in the formation of ROS and will be discussed 




This chapter summarized myocardial metabolism under normal physiological conditions and 
briefly focused both on FA and carbohydrate metabolism - highlighting the most important 
aspects of glycolysis, the TCA cycle and the ETC. The next chapter will focus on metabolic 
derangements that can occur with hyperglycemia and subsequent pathogenic effects.  
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Metabolic derangements in the myocardium 
 
The previous chapter focused on myocardial metabolism under normal physiological 
conditions. We now turn our attention to metabolic derangements that may result in 
downstream pathological consequences, with the emphasis on SSB consumption (as it is the 
focus of this study). Here the spotlight will be on the effects of hyperglycemia on oxidative 
stress and flux through the NOGPs. These pathways are an important focus of our laboratory 
and we propose that their activations play a key role in the development of insulin resistance 




The homeostatic control of glucose is dependent on its uptake by various tissues. For 
example, after the ingestion of a carbohydrate-rich meal, blood glucose levels increase and a 
corresponding response is initiated, i.e. insulin produced by pancreatic β-cells acts to lower 
circulating blood glucose levels again. Moreover, insulin availability allow target tissues to 
respond to the hyperglycemic state by increasing glucose uptake, metabolic utilization and 
glycogen storage. Insulin increases glucose transport in fat and muscle cells by stimulating 
the translocation of GLUT4 from intracellular sites to the plasma membrane (Saltiel and 
Kahn, 2001). This therefore shows the crucial role insulin plays in glucose utilization, and if 
the insulin response becomes dysfunctional this can severely impact on mechanisms 
regulating glucose utilization. The relative lack of insulin action on target cells is referred to 
as IR, a multi-faceted and progressive condition that is normally associated with diabetic 
individuals (Shulman, 2000).  
 
IR is associated with a variety of metabolic disorders, with poor lifestyle and dietary 
behavior, such as SSB consumption, contributing greatly to its progression. Although skeletal 
muscle and adipose tissues are the main target organs of insulin action, IR and subsequent 
derangement of glucose utilization may also impact on cardiac metabolism and function (Hu 
et al., 2008; reviewed by Poornima et al., 2006).  
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The influence of hyperglycemia (e.g. pre-Diabetes/Diabetes, poor dietary choices like 
increased SSB consumption, etc.) on the dysregulation of glucose homeostasis, IR and the 
development of cardiovascular complications has not been given much attention in the 
literature. It is therefore of great importance to address this topic. Since hyperglycemic 
episodes may lead to IR, T2D and CVD over time, the controlled regulation of SSB 
consumption could potentially play a significant role to prevent such detrimental outcomes 
(Brownell et al., 2009; Joseph et al., 2014; Mapanga et al., 2012).  
 
The aim of this study is to investigate the role of SSBs within this context and to assess if it 
induces hyperglycemia and thereby dysregulates myocardial glucose metabolism, i.e. by 
NOGP activation, and the subsequent onset of IR and CVD. This chapter therefore reviews 
mechanisms whereby hyperglycemia alters glucose metabolism, resulting in oxidative stress 





Two forms of hyperglycemia exist, i.e. chronic and acute. Chronic hyperglycemia is defined 
as constantly elevated blood glucose levels over a prolonged period of time and has been 
linked with obesity and CVD (Rubin et al., 2012). Acute hyperglycemia is defined as a 
sudden and dramatic spike in blood sugar, and can sometimes be a serious condition that can 
result in immediate and/or lasting damage (Raposeiras-Roubín et al., 2011)- which will be 
discussed later. We will focus on acute hyperglycemia, as there is limited evidence for the 
potential damaging effects of acute hyperglycemia e.g. caused by increased SSB 
consumption. Furthermore, understanding the early molecular events which perturbs glucose 
metabolic pathways may help us to gain insight into effective intervention strategies to blunt 
such effects. 
 
A number of studies implicate hyperglycemia as an active, causative factor for cardio-
metabolic and vascular dysfunction. For example, our laboratory found that short-term 
hyperglycemic exposures play an essential role in the progression of IR and cardiac 
dysfunction (Joseph et al., 2014; Mapanga et al., 2012). For the current study we therefore 
hypothesize that increased consumption of SSBs induces abnormal postprandial 
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hyperglycemic excursions subsequently leading to perturbed myocardial glucose metabolism, 
with detrimental consequences.  
 
3.2.1 Acute hyperglycemia 
 
Postprandial hyperglycemia is a normal phenomenon to clear blood glucose levels following 
a meal, however higher glucose levels may persist when glucose homeostasis is dysfunctional 
and insulin fails to restore blood glucose levels postprandially. The latter condition usually 
manifests during the progression towards T2D when insulin action becomes impaired (Del 
Prato and Tiengo, 2001). The rate of glucose uptake is generally regulated by fasting 
hyperglycemia, and is increased in individuals with higher fasting glucose levels - this is due 
to the mass action effects of hyperglycemia (Mapanga et al., 2012). Acute hyperglycemia 
may present in undiagnosed diabetic cases, IGT or in response to a severe stress episode 
(Lazzeri, 2009). IGT precedes the onset of T2D and is defined as a condition where fasting 
plasma glucose levels decrease below 7 mmol/L, and is associated with a two-hour 
postprandial excursion of between 7.8 and 11 mmol/L (The Diabetes Forum, [s.a.] as adapted 
from the IDF) (as discussed in Chapter 1).  
 
Hyperglycemia in itself can also cause pancreatic β–cell dysfunction, or cause cell death in 
other tissues like the heart - a phenomenon sometimes referred to  as “glucotoxicity’’. In the 
case of the pancreas, this can be caused by the higher demands for insulin stimulation, 
therefore causing hyperinsulinemia which can directly compromise β–cell function. With 
high SSB consumption there is more insulin secretion than normal and this state of 
hyperinsulinemia may in turn lead to IR (Anton et al., 2010; Fagherazzi et al., 2013; Ludwig, 
2002).  
 
3.2.2 Sugar-sweetened beverages and hyperglycemia 
 
The metabolic effects of long term SSB consumption are linked to increased visceral obesity 
and decreased insulin sensitivity (Stanhope et al., 2009). Clinical studies found that fructose-
sweetened beverage consumption increased fasting glucose concentrations within two weeks 
and also strongly elevated postprandial glucose levels. The inverse was true for insulin 
secretion i.e. after a period of two and ten weeks of fructose consumption, significantly lower 
insulin levels were found versus baseline levels (Swarbrick et al., 2008). Studies have shown 
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that fructose does not stimulate the insulin response as is the case with glucose exposure. This 
is due to the liver being its major site of metabolism as well as the relatively low levels of 
fructose transporters (GLUT5) expressed in pancreatic β–cells. Both glucose and fructose are 
absorbed in the small intestine, however, glucose is taken up through GLUT 4 transporters 
and fructose through GLUT 5 transporters. Fructose does not induce the same insulin 
response as glucose due to there being very little GLUT 5 transporters in the pancreas 
(Johnson et al., 2013). Further evidence suggests that the long-term consumption of SSBs 
will increase the risk of developing CVD due to the above mentioned factors (De Koning et 
al., 2012; Tasevska et al., 2014).  
 
Thus, these studies show that SSB consumption may trigger hyperglycemia (Anton et al., 
2010) which subsequently leads to the dysregulation of cardio-metabolism (Joseph and 
Essop, 2014). In addition, other related effects may also include oxidative stress that in turn 
may cause various CV complications (Fagherazzi et al., 2013; Ludwig, 2002). 
 
3.3 Dysregulation of glucose metabolism and diabetic complications 
 
As discussed, hyperglycemia can contribute to a series of vascular complications by initiating 
detrimental molecular events. The mechanisms whereby hyperglycemia may cause metabolic 
derangements remain unclear but increased free radicals and oxidative stress are proposed to 
be key factors in this process (Mapanga et al., 2012; Robins and Swanson, 2014). Here 
increased caloric intake may help explain such detrimental effects, i.e. additional energy 
expenditure increases flux through the TCA cycle and enhances NADH and subsequent ROS 
generation (Van Gaal et al., 2006). Such an upregulation of oxidative stress plays an essential 
role in a range of complications – e.g. β-cell dysfunction and IR onset - making it a central 
factor for the dysregulation of glucose metabolism (Joseph et al., 2014; King and Loeken, 
2004). Therefore, with increased hyperglycemic episodes, subsequent flux in cardiac 
glycolytic pathways is increased forming ROS which causes oxidative stress triggering 
downstream detrimental effects.  
 
3.3.1 Oxidative stress 
 
Oxidative stress is defined as the inability to remove excess oxidants faster than the 
production thereof. The formation of ROS may be triggered by several stimuli, including an 
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elevation in metabolic fuel substrates (reviewed by King and Loeken, 2004). For example, 
studies demonstrated that hyperglycemia may cause an increase in O2
•
 levels, while 
hyperlipidemia could elevate O2
•
 and peroxynitrite levels (Baynes and Thorpe, 1999; Ceriello 
et al., 2002). Such free radicals formed can damage proteins, lipids and nucleic acids, 
resulting in detrimental outcomes. Moreover, increased levels of oxidative stress have strong 
correlations to the development of IR and related conditions, as well as T2D complications 
(Brownlee, 2005). Therefore oxidative stress is proposed to be the common pathogenic factor 
indicating the development of IR, as well as its progression to Diabetes. In addition, oxidative 
stress is also considered a risk factor for developing CVD (Sugamura & Keaney, 2011). In 
light of this, the specific mechanisms linked to the production of ROS will now be further 
described. 
 
3.3.2 The sources of reactive oxygen species 
 
The primary site of ROS production is the mitochondrial ETC. This is where the substrates 
from carbohydrate and FA metabolism are utilized as described in Chapter 2. The ETC drives 
the electron donors (NADH and FADH2) through its protein complexes to form a proton 
gradient which in turn results in the generation of ATP (discussed by Cecchini, 2003). 
Various signals drive mitochondrial ATP production i.e. increased ATP requirement during 
stress responses or greater physical activity, and hence mitochondrial function is tightly 
regulated – the latter includes the production of mitochondrial ROS subsequent to increased 
ETC activity.  
 
Under stressed conditions mitochondria can generate amplified amounts of ROS (reviewed 
by Du et al., 2000). For example, hyperglycemia-mediated ETC-generated ROS production is 
strongly linked to mitochondrial damage associated with diabetic complications (Guzik et al., 
2002). Of note, hyperglycemia (from SSB consumption) also adds to elevated ROS 
production by increasing glycolytic flux which consequently triggers greater oxidative stress 
production (Park at el., 2005). The upregulation of oxidative stress thus plays a significant 
role in a diverse range of complications and may be relevant within the context of chronic 
SSB consumption. 
The mitochondrion generates ROS by the passage of increased electron flow through the 
ETC. Under hyperglycemic conditions the ETC becomes impaired and electrons leak out via 
Co-Q and react with oxygen to form free radicals, e.g. O2
•
, which is highly reactive because 
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of its unpaired electrons (Ceriello, 2005; Joseph et al., 2014). The electrons mainly leak out 
between complexes II and III, and this is evident by the production of O2
•
 ions in diabetic rats 
in response to glycation of complex III (Brownlee, 2005; Rosca et al., 2005). Figure 3.1 
illustrates the chain of events during hyperglycemia-mediated ROS production in the 
mitochondria due to electron leakage. However, whether mitochondrial defects are causative 



























Figure 3.1: Possible mechanism of how increased blood glucose levels lead to the production 
of superoxide. 1-This may occur with the diabetic phenotype or also with greater caloric 
intake by ‘Western’ dietary habits that may increase blood glucose levels due to postprandial 
hyperglycemia. 2- Increased flux through the TCA cycle forms abundant NADH and FADH2 
electron donors. 3- This generates excess flux though the ETC, causing a build-up of electrons 
between the II and III complexes. 4- Electrons then react with oxygen to form increased 
superoxide levels. 
Abbreviations: Tricarboxylic acid cycle (TCA), nicotinamide adenine dinucleotide reduced 
(NADH), flavin adenine dinucleotide reduced (FADH2), adenosine triphosphate (ATP), 
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As discussed, although O2
•
 is implicated in downstream effects such as IR, another species, 
e.g. hydrogen peroxide (H2O2) may also play a role in the dysregulation of insulin signaling 
mechanisms (Anderson et al., 2009). This is evident as mitochondrial dysfunction was 
discovered when examining the morphology of muscle tissue in diabetic patients.  
 
Although mitochondria are a major source of ROS production, recent data suggest that higher 
levels of ROS generation from sources in the cytosol may also play a pathophysiologic role 
(Joseph et al., 2014; Zhou et al., 2010). These include glucose autoxidation, NADPH oxidase 
(NOX) as well as lipogenase, xanthine oxidase, peroxidases and peroxisomes (Ceriello et al., 
2002; Nishikawa et al., 2000). For example, NOX activity as well as O2
•
 production was 
increased in vascular tissue from diabetic patients (Guzik et al., 2002). ROS produced by 
NOX can additionally participate in myocardial apoptosis during hyperglycemic conditions, 
further exacerbating cardio-metabolic problems (Balteau et al., 2011). Thus both 
mitochondrial and extra-mitochondrial ROS sources are vital in the manifestation of cardio-
metabolic pathologies. It is proposed that the initiating event is the formation of 
mitochondrial O2
• 
which triggers initial ROS generation, which in turn further fuels greater 
ROS generation from other extra-mitochondrial sources.  
 
The other side of the coin is of course that cells do possess antioxidant mechanisms to help 
maintain ROS homeostasis (Dhar et al., 2008). Here mitochondria contain intracellular 
antioxidant mechanisms which alleviate the formation of ROS in order to maintain 
homeostasis, e.g. glutathione reductase and peroxidase recycles glutathione between its 
reduced phase (GSH) and its oxidized phase (GSSG). It acts as an antioxidant, converting O2
• 
to H2O2. Superoxide dismutase (SOD) also modifies O2
•
 to H2O2 which is then converted to 
water via catalase (which is also an antioxidant). Three forms of superoxide dismutase exist; 
mitochondrial manganese superoxide dismutase (MnSOD, SOD2), cytosolic copper-zinc 
superoxide dismutase (CuZnSOD, SOD 1) and extracellular dismutase (EcSOD, SOD3) 
(discussed by Tiebosch, 2014). SOD1 is found in the cytoplasm, whereas SOD2 and SOD3 
are found in the mitochondrion and extracellular matrix respectively (McCord and Edeas, 
2005). However, such intracellular antioxidant defence mechanisms are overwhelmed during 
extreme conditions such as hyperglycemia (Brownlee, 2005; Joseph et al., 2014; King and 
Loeken, 2004) with damaging cardio-metabolic outcomes. The focus will now be on 
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downstream metabolic perturbations and the research interest of our laboratory, i.e. increased 
activation of NOGPs. 
 
3.4 Reactive oxygen species and the activation of non-oxidative glucose 
pathways 
 
Glucose utilization begins with glycolysis (cytoplasm) that forms NADH and pyruvate. 
Pyruvate is subsequently transported into the mitochondrion and further oxidized in the TCA 
cycle. However, with enhanced glucose availability and utilization, ROS generation 
increases. As discussed, hyperglycemia-driven flow through the ETC is the source of 
excessive ROS production in the mitochondrion (Nishikawa et al., 2000). In addition, 
increased FA oxidation leads to the formation of NADH and FADH2, therefore, also 
contributing to ROS formation by similar mechanisms as described before (Brownlee, 2005). 
It is proposed that excessive ROS production cause downstream activation of NOGPs which 
will now be discussed in more detail. 
 
3.4.1 Activation of non-oxidative glucose pathways 
 
Under normal physiological conditions, a relatively small percentage of glucose-derived 
intermediates are shunted into the NOGPs. However, these pathways are markedly 
upregulated upon additional glucose substrate availability – acute and chronic hyperglycemia 
(Fagherazzi et al., 2013). Hyperglycemia-mediated oxidative stress (especially O2
•
) is 
proposed to play an essential role in NOGP activation (Brownlee, 2005; Ceriello, 2005). The 
model currently favored is that the production of O2
•
 under hyperglycemic conditions acts as 
a unifying mechanism in the induction of NOGPs.  
 
The idea put forward is that hyperglycemia-mediated ROS causes DNA damage. O2
•
 reacts 
with nitric oxide (NO) to reduce bioavailability, which in turn produces peroxynitrite which 
can also cause DNA damage (Guzik et al., 2002). The damaged DNA subsequently activates 
the repair enzyme poly adenosine diphosphate ribose polymerase (PARP). However, PARP 
can attenuate GAPDH, a key glycolytic enzyme. As a result upstream glycolytic 
intermediates accumulate and can be shunted into upstream NOGPs, i.e. the formation of 
advanced glycation end-product (AGE) pathway, the activation of protein kinase C (PKC) 
and its isoforms, the polyol pathway and the hexosamine biosynthetic pathway (HBP) 
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(Ceriello and Motz, 2004; Giacco and Brownlee, 2010; Nishikawa et al., 2000) (refer to 
Figure 3.2). Our laboratory proposes that both mitochondria and NOX-derived ROS can 
result in NOGP activation under hyperglycemic conditions (Joseph et al., 2014, Joseph and 
Essop, 2014). The next section will provide a more detailed discussion of the 


























Figure 3.2: A schematic representation of increased flux through the glycolytic pathway as well as the 
TCA cycle forming ROS. This in turn induces DNA damage, subsequently activating PARP which 
tries to rectify the damage done to the DNA but simultaneously limits the actions of GAPDH. Glucose 
intermediates are subsequently shunted into upstream NOGPs, i.e. Polyol, HBP, PKC and AGE. 
Abbreviations: aldose reductase (AR), sorbitol dehydrogenase (SDH), glutamine:fructose-6-phosphate 
amidotransferase (GFAT), diacylglycerol (DAG), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), poly adenosine diphosphate ribose polymerase (PARP), reactive oxygen species (ROS),  
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3.4.2 Non-oxidative glucose pathways 
 
As explained, elevated blood glucose levels may therefore contribute significantly to 
observed adverse effects on the myocardium. A brief description of the four NOGPs will now 
be provided.  
 
3.4.2.1 Advanced glycation end products 
 
AGE compounds are complex and have been linked with Diabetes-related complications 
(Singh et al., 2001; Vlassara & Uribarri, 2014). Here reduced carbohydrates such as 
carbonyl compounds and glucose form methylglyoxal (MG) derivatives from a non-
enzymatic reaction. This occurs in the Maillard reaction and the products are referred to as 
AGEs. The production of intracellular AGE precursors is an important mechanism to induce 
intracellular stress (Hartog et al., 2007), and can accumulate in response to oxidative stress 
under diabetic conditions.  
 
AGE precursors can cause damage to cells in various ways. Firstly, it can act by modification 
of intracellular proteins, including those required for gene transcription. AGE precursors can 
also diffuse from the cell and modify extracellular molecules thereby altering cell signaling 
that can subsequently cause cellular dysfunction. Finally, AGE precursors can diffuse out of 
cells and alter circulating proteins e.g. circulating albumins. Such modified proteins may 
trigger a cascade of events by binding to AGE receptors (RAGE), activating the production 
of inflammatory cytokines and/or growth factors, which in turn can cause vascular 
complications (Brownlee, 2005, Doi et al., 1992). The activation of AGEs through RAGEs 
alters enzymatic structure and function by promoting free radical formation (Baynes and 
Thorpe, 1999; McCarthy et al., 2001). Furthermore, studies found that AGE-modified matrix 
protein inhibits cell migration and adhesion of human T-cells (cells responsible for cell-
mediated immunity) (Haucke et al., 2013). 
 
High amounts of MG can accumulate during hyperglycemic excursions which may directly 
increase AGE precursors by the accumulation of glucose-3-phosphate (G-3-P) in the 
glycolytic pathway (Singh et al., 2001; Vlassara and Uribarri, 2014). AGEs are implicated in 
the progression of heart failure in both diabetic and non-diabetic individuals. The formation 
of AGE induces the production of free radicals and also depletes NO concentrations, which 
Stellenbosch University  http://scholar.sun.ac.za
37 
 
can fuel oxidative stress. As NO exerts its effects on vasodilation and anti-proliferation, AGE 
accumulation may therefore result in vascular thickening and endothelial cell dysfunction 
(Singh et al., 2001). Furthermore, the oxidative stress state caused by AGEs activates nuclear 
factor kappa B (NFκB) a pro-inflammatory transcription factor, which in turn can enhance 
















Figure 3.3: A schematic representation of three different mechanisms whereby AGE precursors 
exert harmful effects, causing vascular pathologies. 1- Modifies intracellular proteins. 2- Moves 
out of the cell and modifies extracellular proteins, therefore impacting on cell signaling. 3- 
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3.4.2.2 Protein kinase C activation 
 
The hyperglycemia-mediated accumulation of glycolytic metabolites, e.g. glyceraldehyde-3-
phosphate in glycolysis may drive the synthesis of DAG. DAG in turn will recruit PKC to the 
plasma membrane, allowing for its activation. The levels of DAG content in the heart is 
directly proportional to its blood glucose levels, therefore hyperglycemic episodes result in 
elevated DAG concentrations (Liu et al., 2012). The PKC family consists of a variety of 
different isoforms with the purpose to control functionality of other proteins – accomplished 
by phosphorylating mainly threonine or serine residues. The main PKC isoforms identified 
includes PKC α, β, and δ (Koya et al., 1997; Mapanga et al., 2012). FA may also trigger the 
formation of active PKC thus bringing into play another metabolite that is typically elevated 
with Diabetes (Koya et al., 1997). The activation of PKC may have detrimental downstream 
effects including decreasing the amount of endothelial nitric oxide synthase (eNOS) (causing 
abnormal blood flow), increasing inflammatory markers (e.g. NFκB) and stimulating NOX 
production (thereby increasing already elevated ROS levels) (Ceriello, 2005; Xia et al., 
2006). Furthermore, the dual actions of PKC, i.e. diminishing eNOS and elevating NOX may 









































Figure 3.4: A schematic representation of the activation of protein kinase C (PKC) and the 
detrimental effects thereof. Glucose-3-phosphate is converted into diacylglycerol (DAG) which 
in turn activates PKC isoforms with detrimental outcomes e.g. increased ROS production and 
inflammatory responses. 
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3.4.2.3 Polyol pathway 
 
As glucose concentrations become elevated, aldose reductase (AR) (normally reduces toxic 
aldehydes to inactive alcohols) reduces glucose to sorbitol, which is then oxidized to fructose. 
The AR reaction (i.e. reduction of glucose to sorbitol) consumes NADPH. As NADPH is a 
vital co-factor for the reduction of GSSG to GSH this decreases NADPH availability and thus 
increases intracellular susceptibility to oxidative stress (Brownlee, 2005; Liu et al., 2012).  
 
There are three potential mechanisms by which the polyol pathway could contribute to 
oxidative stress: 1) AR depletes NADPH cofactors as described above, 2) upon the 
conversion of sorbitol to fructose, sorbitol dehydrogenase (SDH) converts NAD
+
 to NADH 
which in turn is a precursor for the formation of NOX, and 3) the converted sorbitol to 
fructose leads to the formation of fructose-3-phosphate (F-3-P), which is converted to AGE 
precursors downstream (Chung et al., 2003) (Figure 3.5).  
 
 















Figure 3.5: A schematic representation of increased flux through the polyol pathway during 
hyperglycemia. Glucose is converted to sorbitol by AR; this subsequently depletes NADPH 
required in the reduction of GSSG to the anti-oxidant GSH. ROS levels subsequently increase 
thereby contributing to intracellular damage. Fructose also increases cellular ROS production as 
its downstream effects activate AGE, thus contributing to intracellular damage. 




3.4.2.4 Hexosamine Biosynthetic Pathway 
 
The HBP is regarded as a metabolic sensor, i.e. it can ‘tag’ metabolic fuel substrates (when in 
excess) to be stored in various storage depots within the host organism (Rossetti, 2000). 
Under normal physiological conditions ~3% of glycolytic intermediates are shunted into this 
pathway. However, this can sharply increase with hyperglycemia (Robinson et al., 1995). 
Here glucose is progressively shunted into the HBP, which converts fructose-6-phosphate to 
glucosamine-6-phosphate and finally to uridine diphosphate (UDP) N-acetyl glucosamine 
after a series of reactions. The fructose to glucosamine-6-phosphate reaction is catalyzed by 
the rate-limiting enzyme, glutamine: fructose-6-phosphate amidotransferase (GFAT). The N-
acetyl glucosamine is tagged onto serine and threonine residues of various intracellular 
proteins, in an O-linked fashion i.e. O-GlcNAc. The proteins are modified using the 
following enzymes: O-linked GlcNAc transferase (OGT) catalyzes the addition of the sugar 
residue onto nucleocytoplasmic proteins; and N-acetylglucosaminidase (OGA) which 
hydrolyzes the removal of the sugar moiety (discussed by Myslicki et al., 2014). 
 
Excessive HBP modification can result in pathogenic changes in gene expression and protein 
function and greater O-GlcNAcylation may contribute to the pathogenesis of IR, diabetic and 
cardiovascular complications (Brownlee, 2005; Du et al., 2000; Jacobsen et al., 1996). The 
HBP also plays a role in modifying the pentose phosphate pathway (PPP), reducing NADPH 
levels and attenuating the anti-oxidative properties of GSH (Joseph et al., 2014; Mapanga et 
al., 2012; Li et al., 1996). Figure 3.6 demonstrates the flux through the HBP and shows how 










































Figure 3.6: Hyperglycemia increases flux through the HBP. The above is a schematic representation of 
how proteins become O-GlcNAcylated which could lead to damaging outcomes. Under hyperglycemic 
conditions fructose-6-phosphate is converted - by a variety of downstream reactions - into uridine 
diphosphate-N-acetyl glucosamine (UDP-GlcNAc). This substrate gets tagged onto proteins which 
may result in pathophysiologic outcomes. 
Abbreviations: O-linked N-acetyl glucosamine (O-GlcNAc), glutamine: fructose-6-phosphate 
amidotransferase (GFAT), uridine diphosphate (UDP), hydroxyl (OH). 





Hyperglycemia exerts glucose metabolic derangements with detrimental downstream effects 
on cellular function. The literature discussed in Chapter 3 demonstrates that hyperglycemic 
events perturb glucose utilization and also causes oxidative damage. The downstream 
molecular derangements induce a series of “unfortunate events’’ that result in activation of 
NOGPs, each contributing to various forms of damage in the myocardium and beyond.  
 
As discussed earlier, various studies have linked SSBs to hyperglycemia and also to 
detrimental outcomes for the host organism. However, the underlying mechanisms whereby 
this actually occurs remain elusive and no study has investigated whether NOGPs can be 
activated with SSB consumption. Moreover, from a more general perspective there is a 
paucity of data regarding mechanisms whereby SSBs may mediate potential detrimental 
effects. In light of this, we therefore initiated this particular project in order to investigate the 
effects of SSB and ASB consumption, respectively, with the aim to establish a unique, 
chronic SSB model that will allow for a comprehensive investigation of underlying 
mechanisms (this work will extend beyond the current MSc study). As a first step in this 
process, this MSc study entailed pioneering research work to establish and characterize the 
experimental SSB model and also examined NOGP activation in the rat heart. The 
methodology is described in Chapter 4, while Chapters 5 and 6 describes our unique findings 
in this regard.  
 
3.6 Hypothesis 
Our central hypothesis is that long-term SSB consumption will perturb glucose metabolism, 
enhance intracellular oxidative stress, leading to NOGP activation in the heart. We further 
propose that such activation may in turn lead to IR and decreased cardiac function – note the 
broader parts of our hypothesis will be investigated at a later stage and does not form part of 
this MSc study. 
 
  




Our aims for this study are: 
 
 Establish a novel in vivo rat model of chronic SSB and ASB consumption (up to six 
months) 
 Monitor dietary behaviour and phenotypic changes 
 Evaluate fasting blood triglyceride, cholesterol and glucose levels 
 Perform oral glucose tolerance tests (OGTTs), biweekly 
 Measure activation of myocardial NOGPs 
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Materials and Methods 
 
4.1 Experimental design and research chapter layout  
 
The aim of this study was to investigate the effects of SSB consumption on weight gain, food 
intake, insulin-mediated glucose metabolism (oral glucose tolerance tests [OGTTs]), and 
blood metabolites such as triglycerides and cholesterol. Furthermore, organ/tissue weights 
(heart, liver, gastrocnemius and visceral adipose) were evaluated and documented as a 
percentage of the rat’s body weight. Histological analysis was conducted along with analysis 
of the degree of NOGP activation in heart tissues. We aimed to gain an improved 
understanding of how SSB intake may contribute to the onset of cardiovascular disease and 
Type 2 diabetes. This approach would provide greater insight into biochemical mechanisms 
and pathways of an intact organism which an in vitro model would not allow. 
 
4.2 Animals and ethics statement 
 
Animals were treated adhering to the Guide for the Care and Use of Laboratory Animals of 
the National Academy of Science (NIH publication No. 85-23, revised 1996). This study was 
executed with the approval of the Animal Ethics Committees of Stellenbosch University 
(South Africa), (Ethics # SU-ACUM13-00012) (Appendix A). 
 
For the experimental procedure, male Wistar rats (n=72) weighing ~200 grams and 
containing no clinical signs of infection were divided into six groups. The groups were 






 and butter (n=12) and 
further divided into three or six month groups (n=6) (Figure 4.1).  The rats were housed three 




























4.3 Experimental procedure 
 
4.3.1 Experimental dosages 
 
The rats were gavaged on a daily basis with an experimental dosage depending on their group 
allocation and body weight classification. The dosage volumes were calculated using their 
surface area to volume ratio (Reagan-Shaw et al., 2007) and animals were gavaged with the 
equivalent of 125 ml (54 calories) of Coca Cola
®
 for a 60 kg adult human being. The water 
and Coke Light
®
 groups received the same volume of experimental dosage as the Coca Cola
®
 
group. Furthermore, the Jive
®
 and butter group volumes were equivalent to the number of 
calories as for the Coca Cola
®
 group (54 calories). Rats were also allocated to a non-gavaged 
control group. Table 4.1 specifies the amount of experimental dosages that the animals 
received in milliliters according to their weight classification.  
 








3 Months     6 Months 
3 Months     6 Months 3 Months     6 Months 
3 Months     6 Months 
3 Months     6 Months 
3 Months     6 Months 
® 





Treatment Volume According to Weight Classification  
Treatment 250-300 g 300-350 g 350-400 g 400-450 g >450 g 
Water  3.2 ml 3.8 ml 4.5 ml 5.1 ml 5.8 ml 
Coca Cola
®
 3.2 ml 3.8 ml 4.5 ml 5.1 ml 5.8 ml 
Coke Light
®
 3.2 ml 3.8 ml 4.5 ml 5.1 ml 5.8 ml 
Jive
®
 2.4 ml 2.9 ml 3.4 ml 3.8 ml 4.4 ml 
Butter 0.3 ml 0.37 ml 0.43 ml 0.5 ml 0.56 ml 
 
4.3.2 Weight and food consumption 
 
Rats were weighed on a weekly basis in order to record percentage body weight gain and 
assess the development of obesity. Food intake was monitored weekly by measuring food 
consumption within and amongst the different groups. This was achieved by initially 
weighing normal rat chow and placing the pellets into rat cages; where after pellets were 
removed and re-weighed after seven days. The difference between the two measurements 
equated to food consumed per cage. This allowed for quantification of food intake per week 
and thereafter the calculation of the average daily consumption per rat. This procedure 
continued for the duration of the study (24 weeks). 
 
4.3.3 Blood sampling 
 
The animals were fasted overnight (at least 12 hours) in preparation for blood sampling. The 
rats were first sedated using 3% isoflurane (Piramal, Bethlehem PA, USA) and thereafter 1 
ml of blood was drawn from the right jugular vein. Food was subsequently provided ad 
libitum and rats were monitored to assess their overall well-being. The blood samples were 
then centrifuged (Spectrafuge
™
 24D, Labnet, Edison NJ, USA) at 13, 952 x g for 5 minutes to 
separate serum that was collected and stored at -80⁰C until further analysis. Blood was drawn 
at the following time points: week #1 (baseline), week #8, week #12 (three months), week 
#16 and week #24 (six months). The blood samples were sent to the National Health 
Laboratory Service (NHLS) at Tygerberg Hospital to evaluate triglyceride and total 
cholesterol levels (mmol/L). 
Table 4.1: Experimental dosage volumes for the different groups according to their body 
weight classifications. 
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4.3.4 Oral glucose tolerance tests (OGTT) 
 
Oral glucose tolerance tests were performed every two weeks (bi-weekly) for the duration of 
the 24 weeks. The rats were fasted overnight to ensure accurate determination of fasting 
blood glucose levels. A small skin prick was made at the tip of the rat’s tail to allow blood 
droplets to form and a glucometer then used to test blood glucose levels (mmol/L). Baseline 
fasting glucose levels were initially tested where after glucose powder was dissolved in 
distilled water (0.86 g/kg) (Mapanga et al., 2012) and rats gavaged and monitored for 120 
minutes. Readings were taken at the following time points (in minutes): baseline (0), 5, 10, 
15, 30, 45, 60 and 120. Once the procedure was completed the animals re-gained access to 
their food and water, and were monitored to ensure their general well-being. 
 
4.3.5 Tissue and organ harvest 
 
Upon the completion of the experimental procedures for both the three and six month groups, 
respectively, rats were euthanized and their organs harvested for further analysis. Here rats 
were sedated using 5% isoflurane (Piramal, Bethlehem PA) and pedal reflexes tested before 
blood was collected and stored as previously stated. Thereafter, heart, liver, gastrocnemius 
muscle and visceral adipose tissue were collected, weighed, and snap-frozen in liquid 
nitrogen for long-term storage at -80ºC. We also collected visceral adipose tissue for the six 
month groups - stored in formalin for histological analysis. Due to limited animal numbers 
we were only able to focus on adipose tissue for histological analyses – other organs will be 




4.4.1 Tissue sample preparation 
Proteins were extracted from the tissue samples for various analytical procedures. Tissues 
were homogenized in ice-cold RIPA buffer (see Appendix B), and then stored at -80ºC. 
Protein content was evaluated by the Bradford method (Appendix C) and the lysates obtained 
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4.4.2 Evaluation of non-oxidative glucose metabolic pathways activation 
 
Commercial kits were used to evaluate markers of NOGP activation: AGE precursors were 
analyzed using the OxiSelect
™
 Methylglyoxal ELISA kit (Cell Biolabs, San Diego CA,USA),  
PKC kinase activity (Abcam, Global Biotech Company, San Francisco CA, USA), polyol 
pathway using a D-sorbitol colorimetric detection kit (Biovision Research Products, 
Mountain View CA, USA). Western blotting was employed to determine HBP activation – 
assessment of total O-GlcNAc levels (Joseph et al., 2014; Mapanga et al., 2012). 
 
4.4.2.1 Methylglyoxal levels (AGE pathway ) 
 
Reduced carbohydrates such as carbonyl compounds and glucose form methylglyoxal (MG) 
derivatives in a non-enzymatic reaction, i.e. the Maillard reaction -products formed are 
referred to as AGEs. The OxiSelect
™
 Methylglyoxal ELISA kit (Cell Biolabs, San Diego 
CA) was therefore employed as it measures MG derivatives as markers for the activation of 
the AGE pathway. The kit measures MG concentrations in protein samples by comparing 
absorbance values to that of known MG-BSA standard curves. 
 
The previously prepared protein lysates were pipetted into the 96-well plate provided and it 
was incubated overnight at 4°C to allow MG markers to attach to the wells. It was 
subsequently probed with an anti-MG specific monoclonal antibody for one hour at room 
temperature on an orbital shaker. The plate was washed seven times followed by an HRP-
conjugate secondary antibody and the plate was incubated at room temperature for an hour on 
the shaker. A substrate solution was added and left for 5-20 minutes to allow for color 
development. A stop solution was then added to the wells to stop the previous enzymatic 
reaction. Thereafter, the plate was immediately read at a wavelength of 450 nm using a 
microplate reader (El 800 KC Junior Universal Microplate reader, Bio-Tek Instruments, 
Winooski VT). MG marker levels were then quantified from the standard curve and were 
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4.4.2.2 Protein kinase C activity assay  
 
The PKC assay was carried out using an ELISA-based method where a synthetic substrate is 
used for PKC activation. This is measured using an antibody that recognizes the 
phosphorylated form of PKC. Detailed instructions were included in the kit to perform the 
assay (PKC kinase activity [Abcam, Global Biotech Company, San Francisco CA]). 
 
In order to prepare the plate (provided), each well was soaked in a Kinase Assay Dilution 
Buffer (50 µL) at room temperature for 10 minutes where after the solution in the wells were 
aspirated. Protein samples, as well as positive and negative controls were added to the wells 
as detailed in the instruction manual. The reaction was initiated by adding 10 µL of ATP to 
each well and the plate was then incubated at 30°C for 90 minutes with gentle mixing every 
20 minutes. The reaction was thereafter terminated by emptying the wells and patting dry the 
plate. A phosphospecific substrate antibody (40 µL) was then added to each well followed by 
a 60 minute incubation period, with shaking every 20 minutes. After several washing steps 
(with wash buffer provided), diluted anti-rabbit IgG: HRP conjugate was added to the wells 
(1:1000 dilution) and incubated for 30 minutes at room temperature. TMB substrate (60 µL) 
was then added to each well and the plate incubated for 30-60 minutes (this time was 
determined by the color development). Stop Solution was added to the wells to stop the 
reaction and the color intensity was recorded at a wavelength of 450 nm using a microplate 
reader (El 800 KC Junior Universal Microplate reader, Bio-Tek Instruments, Winooski VT, 
USA). PKC activity was determined using the standard curve and expressed per volume 
lysate per minute and values normalized to relative standard controls. 
 
4.4.2.3 D-sorbitol levels (Polyol pathway)  
 
When glucose is reduced by aldose reductase, sorbitol is formed and eventually converted 
into fructose. D-sorbitol is an intermediate in the polyol pathway and was here employed as a 
marker of this pathway’s activation. D-sorbitol was measured using a D-sorbitol colorimetric 
detection kit (Biovision Research Products, Mountain View CA). The standards, as well as 
the samples were loaded into the 96-well plate as detailed in the kit’s instruction manual. The 
reaction mix was prepared and pipetted into each well (50 µL) and left to incubate at 37°C for 
30 minutes. Sorbitol levels were determined by evaluating the oxidation of sorbitol to 
fructose. The reaction’s absorbance was determined at 560 nm with a microplate reader (El 
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800 KC Junior Universal Microplate reader, Bio-Tek Instruments, Winooski VT). The 
sorbitol concentration (C) was calculated using the sample amount (nmol) from the standard 
curve (Sa), sample volume used (Sv) and the dilution factor (D); C= Sa / Sv x D. 
 
4.4.2.4 Hexosamine Biosynthetic Pathway (HBP) 
 
We employed Western blotting to determine myocardial HBP activation (Appendix D). 
Collected heart tissues were used to prepare lysates (as previously described) and samples 
stored at -80°C. O-GlcNAc expression was determined using SDS-PAGE electrophoresis and 
Western Blotting (refer Appendix D) with an O-GlcNAc antibody (CTD110.6, Santa Cruz 
Biotechnology, Santa Cruz CA, USA) together with an appropriate secondary antibody (anti-
mouse IgG, HRP-linked, Cell Signaling Technology
®
, Danvers MA, USA). Final O-GlcNAc 
amounts were determined using Image Lab
™
 Software version 4.0, quantification analysis 
(BIO-RAD, Berkley CA, USA). A more detailed description of the imaging process can be 
found in Appendix D. 
  
4.4.3 Histology samples 
 
The collected visceral adipose tissue was fixed in formalin and stained with hematoxylin and 
eosin stain (H&E) to produce histology slides (refer to Appendix E). Tissues slides were 
examined using a Nikon Microscope (Nikon Eclipes E400, Tokyo Japan) at a 10X 
magnification and photographed with NIS Elements (Imaging software version 4.10, Tokyo 
Japan). The surface area of the adipose tissue was calculated using ImageJ software (ImageJ 
1.47v, Java 1.6.0_20). 
 
4.5 Statistical analysis 
 
The data is presented as mean ± standard error of the mean (SEM). Differences between 
groups were analyzed using Mann-Whitney unpaired t-tests. Where more than two groups 
were present, the one-way analysis of variance (ANOVA) was used. All statistical analyses 
were conducted using Graphpad Prism 5.01 (Graphpad Software Inc, San Diego CA, USA). 
Values were considered significant when P<0.05. 
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Chronic SSB model – baseline characterization (weights, 
metabolite levels) 
 
Although limited studies have previously linked SSBs to hyperglycemia, no-one (as far as we 
know) has undertaken a comprehensive investigation to evaluate how SSB consumption may 
mediate detrimental physiological effects on the heart. In light of this, this study aimed to 
investigate the effects of chronic consumption of different SSBs and ASBs by establishing a 
unique in vivo rat model. As this thesis was the beginning of this challenge, we began by 
performing some baseline characterization of SSB treatment in terms of weight changes and 
key systemic metabolites – covered in Chapter 5. We also investigated whether myocardial 
NOGPs – our laboratory’s research focus – would be activated in our newly established rat 
model of chronic SSB consumption – Chapter 6.  
 
5.1 Percentage weight gain (from baseline) 
 
We initially evaluated the percentage increase in body weight (from baseline [day 1]) over a 
period of 24 weeks for each of the different experimental groups here investigated (Figure 
5.1). Our data reveal that there were no significant differences detected for any of the groups 
– for the entire duration of the experiment.  
 
  




Figure 5.1: The percentage weight gain over a period of 24 weeks. A: Coca Cola
®




, D: butter. Weeks 1 
- 12, n=12; weeks 13 to 24, n=6 – for all groups except butter. For the butter group: weeks 1 - 12, n=11; weeks 13 - 24, n=5. 
A B 
C D 
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5.2 Food consumption 
 
The food consumption of the rats was also monitored for the entire duration of the 
experiment (Figure 5.2). However, we found no significant differences in food consumed by 









Figure 5.2: Food consumption over 24 weeks. A: Coca Cola
®




, D: butter. 
Weeks 1 - 12, n=12; weeks 13 - 24, n=6 – for all experimental groups except the butter group. Butter 
group: week 1 - 12, n=11; weeks 13 - 24, n=5. 
B A 
C D 
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5.3 Key systemic metabolites 
 
To gain further insights into the effects of SSB consumption, we also determined total plasma 
cholesterol, triglyceride and glucose levels (fasted) at various time intervals (Figures 5.3 - 







group exhibited no differences in cholesterol levels at baseline, two, four and 
six months. However, at three months, there were higher cholesterol levels compared to the 
water group (P<0.05). For triglyceride levels there were no differences at baseline, three, four 
and six months. However triglyceride levels for the Coca Cola
®
 group were higher than the 
water group at the two month time point (P<0.05) (refer to Figure 5.3). For the glucose 
measurements, during week one there was significance with Coca Cola
®
 presenting higher 
fasting blood glucose levels than those of the control group (P<0.05). At three months fasting 
blood glucose levels were lower compared to the control group (P<0.001). No significant 





No significance was seen at baseline and four months between the three groups. There were 
elevated cholesterol levels in the Coke Light
® 
group at two and three months, respectively, 
when compared to the water group (P<0.05). After six months the Coke Light
®
 group showed 
decreased cholesterol levels compared to the water group (P<0.05). The triglyceride data 
revealed no changes at baseline, two, three and four months, respectively. However, we 
found a reduction at the six month time point when compared to the control and water groups 
(P<0.05) (refer to Figure 5.4). Results from week 1 indicated no significant fasting blood 
glucose levels. At three months Coke Light
®
 had reduced fasting glucose levels compared to 
the control group (P<0.001). The six month results revealed no significant differences 







 group displayed no differences for cholesterol levels after two and six months, 
respectively, however, the baseline results reflecting higher levels than the control group 
(P<0.05). After three and four months, respectively, the Jive
®
 group showed elevated 
cholesterol levels compared to the water group (P<0.001 & P< 0.05, respectively). There 
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were no significant differences observed for triglyceride levels during any of the measured 
time points (refer to Figure 5.5). During week 1, Jive
®
 showed elevated glucose levels at 
baseline (fasting glucose) versus both the control and water groups (P<0.001 and P<0.01, 
respectively). At the three month time point, Jive
®
 presented with lower fasting glucose 
levels when compared to respective control and water groups (P<0.001 and P<0.05, 




The baseline cholesterol tests for the butter group revealed no significant differences as well 
as after four and six months, respectively. However, after two months the butter group 
exhibited elevated cholesterol metabolites compared to the water group (P< 0.05). After three 
months the butter group displayed significance between the control and water groups (P< 
0.05). The triglyceride levels remained unchanged at baseline, three, four and six months, 
respectively, but at two months it showed higher triglyceride levels than both the control and 
water groups (P<0.01) (refer to Figure 5.6). Week one’s results revealed no significance 
between the groups fasting blood glucose levels. At three months the butter group exhibited 
elevated fasting blood glucose levels compared to the water group (P<0.01). Again at six 
months, the butter group had higher fasting glucose levels compared to the water group 
(P<0.05) (Figure 5.7). 








Figure 5.3: Coca Cola
®
- cholesterol and triglyceride blood metabolites. Blood was 
collected at 0, 2, 3, 4 and 6 months, respectively (n=12 for baseline to three months; n=6 
for four to six months). Values are expressed as mean ± SEM. Significance is shown as * 
P<0.05. 









Figure 5.4: Coke Light
®
- cholesterol and triglyceride blood metabolites. Blood was 
collected at 0, 2, 3, 4 and 6 months. Values are expressed as mean ± SEM. Baseline to 
three months n=12 and four to six months n=6. Significance is shown as * P<0.05. 










- cholesterol and triglyceride blood metabolites. Blood was collected at 
0, 2, 3, 4 and 6 months. Values are expressed as mean ± SEM. Baseline to three months 
n=12 and four to six months n=6. Significance is shown as * P<0.05 and ** P<0.005. 










Figure 5.6: Butter- cholesterol and triglyceride blood metabolites. Blood was collected at 
0, 2, 3, 4 and 6 months. Values are expressed as mean ± SEM. Baseline to three months 
n=12 and four to six months n=6. Butter baseline to three months n=11 and four to six 
months n=5. Significance is shown as * P<0.05. 









Figure 5.7: Fasted plasma glucose concentrations. A: Coca Cola
®





, D: butter. Weeks 1 - 12, n=12; weeks 13 - 24, n=6 – for all experimental groups 
except the butter group. Butter group: week 1 - 12, n=11; weeks 13 - 24, n=5. 
Significance is shown as * P<0.05, ** P<0.005 and *** P<0.0005. 
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5.4 Organ mass analyses 
 




 group results after three months revealed no significance between the 
different groups for heart, muscle, liver or visceral fat weights. A similar pattern was found at 
the six month time point, except for the liver mass that displayed a decrease compared to both 
the control and water groups (P<0.05 and P<0.005, respectively) (Figure 5.8). 
 
For the Coke Light
®
 group we found no differences between the heart, liver and visceral 
adipose weights after three months. However, the Coke Light
®
 group exhibited heavier 
muscle weights than the control group (P<0.005). After six months there were no significant 
differences for heart and muscle weights, although we found lowered liver mass versus both 
the control and water groups (P<0.005 and P<0.001, respectively). In addition, the Coke 
Light
®
 group displayed heavier visceral fat mass compared to the control group (P<0.01) 




 group there was no difference between the heart, liver and visceral fat weights 
after three months despite displaying lighter muscle weight compared to the water group 
(P<0.005). However, the Jive
®
 group exhibited greater heart (P<0.01), muscle (P<0.005) and 
liver masses (P<0.05 and P<0.005, respectively) at six months compared to both the control 
and water groups. Furthermore, the Jive
®
 group also displayed increased visceral fat mass 
when compared to the control group (P<0.01) (Figure 5.10). 
 
For the butter group the data indicated that there was no significant difference between heart 
weights after three months. However, the butter group’s muscles were lighter than the water 
group (P<0.01) while liver weights were increased versus control and water groups (P<0.05 
and P<0.001, respectively). This group’s visceral fat also weighed significantly less than the 
control group (P<0.05). We found no significant differences after six months (Figure 5.11).  
  






Figure 5.8: Coca Cola
®
- organ and tissue weights as a percentage of total body mass (n=6). 
Values are expressed as mean ± SEM. Significance is shown as * P<0.05 and ** P<0.005. 




Figure 5.9: Coke Light
®
 - organ and tissue weights as a percentage of total body mass (n=6). 
Values are expressed as mean ± SEM. Significance is shown as * P<0.05 and ** P<0.005. 






- organ and tissue weights as a percentage of total body mass (n=6). Values 
are expressed as mean ± SEM. Significance is shown as * P<0.05 and ** P<0.005. 




Figure 5.11: Butter- organ and tissue weights as a percentage of total body mass (n=6 for all 
except n=5 for 6-months butter group). Values are expressed as mean ± SEM. Significance is 
shown as * P<0.05 and ** P<0.005. 
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5.5 Adipocyte area analyses 
 
The total area of visceral adipocytes was measured only at six months – due to limited tissue 
availability (Figure 5.12). The Coca Cola
®
 group displayed increased fat cell surface area 
compared to both the control and water groups (P< 0.05 and P<0.0001, respectively). A 
similar result was found for the Coke Light
® 
group, although only significant when compared 
to the water group (P< 0.005). Conversely, the Jive
®
 group exhibited reduced fat cell surface 
area compared to both the control and water groups (P<0.0001 and P< 0.005, respectively). 
No significant differences were found for the butter group. Figure 5.13 display an example of 





















, D: butter. The left visceral fat pad was collected from each group (n=6), 
butter (n=5). Twelve images were taken of each group and 110 adipocytes were measured (µm
2
) 
per group. Values are expressed as mean ± SEM. Significance is shown as * P< 0.05, ** 
P<0.005 and *** P<0.0005. 
A B 
D C 


























D E F 
C B 
Figure 5.13: Histological images used to calculate the area of the fat cells. Twelve images were taken of each group and 110 adipocytes were 
measured (µm
2
) per group. A: Control, B: Water and C: Coca Cola
®




, F: Butter 
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Chronic SSB model – baseline characterization (glucose 
metabolism, NOGP activation) 
 
6.1 Oral glucose tolerance tests 
 
The results of OGTTs, which were performed bi-weekly over a period of six months, are 
reflected in Figures 6.1 to 6.8. Each treatment group’s results are shown separately. Only 
baseline, three and six months results will be shown, as the animals were sacrificed at three 




Results from week one indicated no significant differences at the 15 minute time point. At 30 
minutes the Coca Cola
®
 group displayed significantly reduced blood glucose levels compared 
to water, while at 120 minutes Coca Cola
®
 generated variable data versus control and water 
groups, respectively (P<0.005 and P<0.0001). At three months there was no significance at 
30 and 120 minutes, however, at 15 minutes lower glucose levels were observed compared to 
the control group (P<0.001). The six month results indicated no significant differences at 30 
minutes. At 15 minutes there was a significant increase in Coca Cola
®
 blood glucose levels 
compared to both the control and water groups (P<0.005 and P<0.05, respectively). There 
was also a significant reduction in the Coca Cola
®
 glucose levels compared to the water 




Results from week one indicated significance, at 15 minutes with the Coke Light
®
 group 
exhibiting significantly elevated glucose levels compared to the water group. After 30 
minutes Coke Light
® 
showed diminished glucose levels versus the
 
control and water groups 
(P<0.05 and P<0.0005, respectively), while at the 120 minute time point there were various 




the two groups (P<0.05 and P<0.005, 
respectively). At three months the Coke Light
®
 had significantly reduced glucose levels at 15, 
30 and 120 minutes compared to the control group’s respective time points. The six month 
results revealed no significant differences between the groups at 30 and 120 minutes. 
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levels compared to the control and water groups (P<0.01 and P<0.05, respectively) (refer to 




During week one, Jive
®
 showed significantly elevated glucose levels at 15 minute and 
variable difference at 120 minute versus both the control and water groups. By contrast, at 30 
minutes the Jive
®
 displayed lowered glucose levels compared to the water group (P<0.0005). 
At the three month time point, Jive
®
 presented with lower glucose levels at 15 minutes when 
compared to respective control and water groups (P<0.0001 and P<0.0005, respectively). The 
Jive
®
 group levels were also significantly lower than the water group at the 30 minute time 
point, but no differences were observed at 120 minutes. At six months there were no 
significant differences between the groups at 15 and 30 minutes. However, Jive
®
 was 
significantly lower than both the control and water groups at 120 minutes  (refer to Figures 
6.5 & 6.6). 
 
6.1.4 Butter 
Week one’s results revealed no significance at 30 minutes. However, the butter group showed 
lower blood glucose levels than the control group at 15 minutes (P<0.05), while at 120 
minutes it showed higher levels versus the control group (P<0.0001). At three months the 
butter group showed reduced blood glucose levels at 15 minutes compared to the control 
group (P<0.0005). No further significance was found at 30 or 120 minutes. At six months, the 
butter group had significantly greater blood glucose levels than both the control and water 
groups at 15 minutes. There was no significance at 30 or 120 minutes for the six month time 
period (refer to Figures 6.7 & 6.8). 
  





Figure 6.1: Coca Cola
®
- Oral glucose tolerance tests performed at various stages over the course of the six month experimental 
period. Glucose levels were tested at 0, 5, 10, 15, 30, 45, 60 and 120 minutes (n=6). Values are expressed as mean ± SEM. 
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Figure 6.2: Coca Cola
®
- Oral glucose tolerance tests indicating glycemic state (n=12 for 
baseline [week 1] to three months; n=6 for six the month time point). Values are expressed as 
mean ± SEM. Significance is shown as * P<0.05, ** P<0.005 and *** P<0.0005. 




Figure 6.3: Coke Light
®
- Oral glucose tolerance tests indicating glycemic state. Glucose levels were tested at 0, 5, 10, 15, 30, 45, 60 and 
120 minutes (n=12 for baseline [week 1] to three months; n=6 for the six month time point). Values are expressed as mean ± SEM.  
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Figure 6.4: Coke Light
®
- Oral glucose tolerance tests indicating glycemic state. (n=12 for 
baseline [week 1] to three months; n=6 for the six month time point). Values are expressed as 
mean ± SEM. Significance is shown as * P<0.05, ** P<0.005 and *** P<0.0005. 






- Oral glucose tolerance tests indicating glycemic state. Glucose levels were tested at 0, 5, 10, 15, 30, 45, 60 and 120 
minutes (n=12 for baseline [week 1] to three months; n=6 for the six month time point). Values are expressed as mean ± SEM.  
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- Oral glucose tolerance tests indicating glycemic state (n=12 for baseline [week 
1] to three months; n=6 for the six month time point). Values are expressed as mean ± SEM. 
Significance is shown as *P<0.05, ** P<0.005 and *** P<0.0005. 




Figure 6.7: Butter- Oral glucose tolerance tests indicating glycemic state. Glucose levels were tested at 0, 5, 10, 15, 30, 45, 60 
and 120 minutes (n=12 for baseline [week 1] to three months; n=6 for the six month time point for all experimental groups 
except the butter group. Butter group: week 1 - 12, n=11; weeks 13 - 24, n=5.). Values are expressed as mean ± SEM.  
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Figure 6.8: Butter- Oral glucose tolerance tests indicating glycemic state. Baseline (week 1) to three 
months n=12; six months n=6 for the control and water groups; baseline to three months n=11; six 
months n=5 for the butter group. Values are expressed as mean ± SEM. Significance is shown as * 
P<0.05 and *** P<0.0005. 
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6.2 Non-oxidative glucose pathway in the heart  
 
OGTTs were performed biweekly in order to monitor the animal’s glycemic states and to 
evaluate the effects of SSBs, ASBs and butter on postprandial hyperglycemic excursions. 
This model was created to replicate acute hyperglycemic events by daily gavaging animals 
with various experimental substances. Although NOGPs are not formal risk factors to test for 
the development of IR or T2D, they are associated with hyperglycemia, and if activated 
continually may eventually lead to T2D and cardiac dysfunction. Together hyperglycemia 
and its downstream activation of NOGPs can lead to metabolic derangements within the 
myocardium and contribute to the onset of cardiovascular complications. 
 
6.2.1 Advanced glycation end products (AGE) 
 
The levels of MG were measured in order to determine activation of the AGE pathway – refer 
Figure 6.9. Significant differences were found at three months, i.e. the Coca Cola
®
 group 
displayed lower MG levels compared to the water group. However, there were no differences 




group showed a decrease at three months compared to the water group 
(P<0.01). The six month results show  elevated MG levels in the Coke Light
®
 group 
compared to the control group (P<0.05). 
 
At three months the Jive
®
 group exhibited significantly higher MG levels compared to the 
control group but at six months levels were significantly lower than both the control and 
water groups. 
 
At three months the butter group showed higher MG levels compared to the control groups 








Figure 6.9: Activation of the AGE pathway. A: Coca Cola
®




, D: butter (n=6 for all groups except butter group for six 
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6.2.2 Protein kinase C (PKC) activity 
 
Heart tissues were analyzed to determine the activation of PKC but no significant differences 
were observed between the Coca Cola
®
, control and water groups at three or six months 
(refer to Figure 6.10).  
 
No significant differences were detected at three months between the control, water and Coke 
Light
® 
groups. However, at six months there was an increase in PKC activity in the Coke 
Light
® 
group compared to both the control and water groups (P<0.01 and P<0.05, 
respectively).  
 
At three months Jive
®
 displayed significantly greater PKC activity than both the control and 
water groups, that was largely sustained after six months (compared to control group only) 
(P<0.05).  
 
There was no significant PKC activity found in either the three or six month time points 
between the control, water and butter groups. 




Figure 6.10:  PKC activity in cardiac tissues. A: Coca Cola
®




, D: butter (n=6 per group except for the butter group at six months 
[n=5]). Values are expressed as mean ± SEM. Significance is shown as * P<0.05 and ** P<0.005. 
A B 
C D 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
97 
 
6.2.3 Polyol pathway 
 
D-sorbitol levels were measured in order to calculate activation of the polyol pathway – refer 
Figure 6.11. At three months there were significantly depleted D-sorbitol levels in the Coca 
Cola
®
 group compared to both the control and water groups (P<0.01 and P<0.005, 
respectively). However, at six months no significant differences were identified.  
 
At three months the Coke Light
® 
group showed a significant increase in D-sorbitol levels 
compared to both the control and water groups, while no differences were found at the six 
month time point.  
 
At three months the D-sorbitol levels were significantly higher in the Jive
®
 group compared 
to the control and water groups. The inverse was observed at six months with significantly 
reduced glucose levels compared to the respective control groups.  
 
At three months the butter group showed higher amounts of D-sorbitol when compared to 
both the control and water groups (P<0.01 and P<0.005, respectively). However, at six 
months there were no significant differences found. 
  




Figure 6.11: Activation of the polyol pathway. A: Coca Cola
®




, D: butter (n=6 per group except for the butter group at six 
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6.2.4 Hexosamine biosynthetic pathway (HBP) 
 
Western blotting techniques were employed to calculate O-GlcNAcylated proteins, which 
were measured in order to determine HBP activation – refer Figures 6.12 and 6.13. Note, 
Figure 6.13 represents typical Western blot images used to generate the quantified data 
presented here. The various lanes in the gel, used to separate proteins, were loaded with 
proteins extracted from the rat hearts. 
 
Three months revealed no significant difference between the control, water and Coca Cola
®
 
groups. However, at six months the total O-GlcNAcylated proteins were elevated in the Coca 
Cola
®
 group compared to both the control and water groups (P<0.01).  
 
At three and six months there were significantly elevated O-GlcNAc protein levels in the 
Coke Light
®
 group compared to the control and water groups.  
 
At both three and six months the Jive
®
 displayed more O-GlcNAcylated proteins when 
compared to the control (P<0.005 and P<0.01, respectively) and water (P<0.01) groups.  
 
At three months the butter exhibited significantly higher amounts of O-GlcNAcylated protein 









Figure 6.12: Total O-GlcNAcylated proteins used to measure activation of the HBP. A: Coca Cola
®




, D: butter (n=6 per 
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 Figure 6.13: Representative Western blot images used to quantify the total O-GlcNAcylated proteins in the heart.  
 





  Coke Light
®
   Jive
®
 Butter 
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Cardiovascular complications contribute dramatically to morbidity and mortality incidence 
amongst individuals who have developed T2D, with IR in the myocardium playing an 
important role in such disease progression (Chavali et al., 2013). It is well established that 
effective glucose uptake and metabolism contribute greatly to normal cardiac function and 
limiting future onset of CVD (Liao, 2002). However, poor lifestyle choices and dietary habits 
e.g. increased SSB consumption, may give rise to acute hyperglycemic events (Popkin, 2012) 
and perturb normal cardiac metabolism leading to increased manifestation of risk factors such 
as increased weight gain, IR and T2D (De Ruyter et al., 2012). Despite the proposed risk 
posed by increased SSB consumption, the underlying mechanisms whereby it can result in 
cardio-metabolic complications remain poorly understood. In light of this, the  experimental 
design of this study was to establish (and characterize) a unique rat model of chronic SSB 
consumption with the idea of determining risk factors and mechanisms that contribute to the 
development of cardio-metabolic diseases.   
 
7.2 Major findings 
 
The current study managed to successfully establish an in vivo rat model of chronic SSB 
consumption. Our data reveal that after six months of consuming the different sodas, the 
groups display minimal macroscopic changes (similar body weights and circulating 
metabolite levels), therefore possibly representing a relatively early stage in terms of 
expected SSB-mediated cardio-metabolic complications. However, we found several changes 
at the biochemical level with distinct signatures for the Jive
®
 group compared to the Coca 
Cola
®
 and Coke Light
®
 groups. Here Jive
®
 consumption for six months resulted in early signs 
of cardiac and skeletal muscle hypertrophy, together with increased liver mass and perturbed 
adipocyte ultrastructure. Moreover, these animals displayed variable OGTTs suggesting that 
insulin-mediated glucose metabolism may be altered, although no clear signs of IR were 
found after six months. In addition, we also established that the majority of the NOGPs were 
activated in heart tissues isolated from the Jive
®
 group after three months, and sustained after 
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six months. We propose that such sustained activation may have contributed to some of the 
changes already found and may also contribute to the onset of future complications. The 
Coca Cola
®
 and Coke Light
®
 groups exhibited alterations in liver mass and altered adipocyte 
ultrastructure together with lower glucose clearance after six months (OGTTs). The latter 
suggests that these groups may be IR or at least in the process of becoming so. Here we 
established that cardiac NOGPs were activated to a lesser extent compared to the Jive
®
 group, 
although the HBP was strongly turned on in both Coca Cola
®
 and Coke Light
®
 groups and 
may thus be implicated in the OGTT response observed, as also likely to contribute to the 
onset of  future cardio-metabolic complications. 
   
7.3 Cardiovascular risk factors  
 
7.3.1 Weight gain and food consumption 
 
For the first part of our study we focused on the weight gain of the animals and their 
associated food consumption as numerous studies indicate that there is a parallel weight gain 
with the consumption of SSBs (De Ruyter et al., 2012; Ebbeling et al., 2012; Qi et al., 2012). 
This relationship is postulated to be due to the increased caloric intake and the inability of 
SSBs to trigger the satiety response, thus providing an explanation for greater energy intake 
(Malik et al., 2010; Popkin, 2012) which is not utilized perhaps due to sedentary lifestyle 
choices (Bradshaw et al., 2007).  
 
Our data revealed that all the soda groups consumed similar amounts of food regardless of 
their treatment group, with no significant changes in terms of overall weight gain. These 
findings therefore show that the consumption of SSBs, ASB or butter did not affect dietary 
patterns/behavior and weight gain in our experimental model. How does one explain this 
discrepancy with previously published clinical studies? We propose two reasons. In the first 
instance, this may relate to the length of time of SSB consumption. For example, clinical 
studies examined human subjects over a relatively long period, e.g. two years, and under 
these circumstances found SSB consumption linked to weight gain and/or an increase in BMI 
(De Ruyter et al., 2012; Ebbeling et al., 2012). Therefore, we propose that a period of 24 
weeks (the entire duration of this study) may not have been long enough to trigger significant 
changes in terms of weight gain. However, this may provide useful support for any 
metabolic/signaling changes found, i.e. that this not due to obesity per se but rather due to 
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SSB/ASB effects itself (Malik et al., 2010; Van Gaal et al., 2006). A second reason may also 
be due to variations in dosages employed. For the current study, we employed a dosage that is 
roughly equivalent to half a glass of soda consumed per day (in human terms) while in some 
clinical studies they typically requested participants to consume ~ 355 ml of soda per day (De 
Koning et al., 2012; Ebbeling et al., 2012).  The treatment dosages were calculated as 
described in Chapter 4. 
 
7.3.2 Cholesterol and Triglyceride Blood Markers  
 
We next aimed to test whether the consumption of SSBs would trigger a rise in systemic 
cardio-metabolic risk factors. Blood metabolites (cholesterol, triglycerides, glucose) 
associated with the risk of developing CVD were therefore assessed after three and six 
months, respectively (Swarbrick et al., 2008). Our data did not reveal many significant 
changes and no distinct patterns/trends. We did, however, find sporadic changes, e.g. 
increased triglyceride levels for the Coca Cola
®
 group at two months, and decreased levels 
for the Coke Light
®
 group after six months. The same applies for cholesterol and glucose 
(baseline) measurements and we are of the opinion that such isolated changes may be 
dependent on the particular context and/or rat grouping at the time of the measurements. Our 
analyses were further compounded by some minor variations between the control and water 
groups (also for other measurements) and hence we only took soda-induced changes as real 
when it differed significantly from both control groups. We are unclear why this may be the 
case and postulate this may be due to the number of animals examined per group, i.e. higher 
numbers per group may potentially remove such differences. In addition, animal 
heterogeneity may also account for such changes. At present, we are also currently 
conducting further research studies to evaluate additional risk factors e.g. lipid deposition in 
heart, liver and muscle tissues. 
 
How do such findings match with clinical studies completed? Ludwig (2002) reviewed two 
separate studies and found that higher glycemic load was accompanied by an agonistic 
increase in serum lipid concentrations, i.e. cholesterol and triglycerides. Conversely, his 
additional analyses on six other SSB-related studies showed no significant effects for these 
metabolites. Several studies support this notion, e.g. by Fung et al. (2001) concluded that 
SSB consumption resulted in no significant differences in terms of cholesterol and 
triglyceride levels. Moreover, Swarbrick et al. (2008) examined the effect of fructose-
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sweetened beverages (a component of SSBs) over a period of 10 weeks and also established 
no significant differences for fasting blood cholesterol and triglyceride levels. Others likewise 
found no changes in cholesterol levels for individuals consuming SSBs and ASBs, although 
triglyceride levels were significantly increased with the consumption of SSBs but not with 
ASBs (De Koning et al., 2012). Thus, the overall data are mixed with some studies reporting 
changes in lipid levels while others do not. It is likely that such variations may be due to the 
nature and experimental design of different studies and the degree and nature of SSB 
consumption. In our experimental model, we propose that the time period and the dosages 
employed represent a moderate stressor and hence we do not observe any significant 
macroscopic changes after the six-month time period. We are of the opinion that this is 
actually a strength of our newly established experimental model since it should provide 
useful insights into biochemical/signaling/gene changes that would occur in the absence of 
significant weight and circulating metabolite levels. Such molecular changes would therefore 
represent the earliest changes triggered in response to long-term SSB/ASB consumption.    
 
7.3.3 Organ mass analyzes 
 
Several organs and tissues (heart, muscle, liver and visceral adipose tissue) were weighed at 
three and six months, respectively. We calculated the mass of each organ as a percentage of 
body weight in order to gain further insights into the effects of SSBs and ASBs. For the 
purpose of this discussion each organ/tissue will be discussed separately.  
 
7.3.3.1 Heart mass 
 
Neither our three nor six month results showed any differences with regards to heart mass, 
except at six months for the Jive
®
 group. This finding is intriguing since the greater heart 
mass suggests that such hearts may be undergoing a hypertrophic response. We are currently 
in the process of evaluating additional biomarkers for cardiac hypertrophy such as Atrial 
natriuretic peptide (ANP) and B-type Natriuretic Peptide BNP. Moreover, we are planning 
future studies to collect heart tissues for histological analyses in order to assess whether this 
indeed represents a hypertrophic response. We are unclear at this stage how exactly this 
phenomenon may occur in response to SSB intake, but Maersk et al. (2012) found that SSB 
exposure resulted in an increase in blood pressure in adult individuals. Thus it is a possibility 
that Jive
®
 consumption may have increased blood pressure thereby placing hearts under more 
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strain to pump blood to the entire body and potentially leading to the onset of cardiac 





7.3.3.2 Muscle mass 
 
The muscle mass data for the Jive
®
 group correlated well with the heart mass findings earlier 
discussed. These data suggest that for the Jive
®
 group there may be a general activation of 
growth signals in muscle (skeletal, heart) tissues and it correlates with work done by Maersk 
et al. (2012). More research is now required to gain a comprehensive understanding of the 
effects of SSBs and ASBs on muscle growth and several growth pathways e.g. insulin-like 
growth factor (IGF)-1 and/or signaling via the Akt/mammalian target of rapamycin pathways 
that are likely  prime candidates in this regard (Tidball, 2005). 
 
7.3.3.3 Liver mass 
 
For the liver mass evaluations we found mixed results with it being increased and decreased, 
for different groups at varying times. Here the Jive®-treated animals displayed increased 
liver mass after 6 months, while a similar finding was made for the butter group – but at the 3 
month time point. Conversely, both Coca Cola® and Coke Light® exhibited decreased liver 
mass weights compared to the control groups. We are unclear why such distinct differences 
manifest and are in the process of completing additional biochemical studies to gain 
additional insights into these findings. The higher liver mass data are in agreement with 
Maersk et al. (2012) and Popkin (2012) who also found  increased liver fat percentages with 
the consumption of SSBs (clinical studies). Moreover, the same authors also reported that 
ASB consumption was linked to lower liver weights (Maersk et al., 2012). The Coca Cola® 
data, however, contradict these findings by also showing reduced liver mass, although this 
may be due to its high fructose content that is rapidly metabolized in the liver (De Koning et 
al., 2012). The Coca Cola
®
 results may also be due to the metabolism of fructose in the liver. 
The observation that fructose-fed rats develop fatty liver and metabolic syndrome without 
requiring increased energy intake suggests that the metabolism of fructose may be different 
from that of other carbohydrate sources.  
 
Stellenbosch University  http://scholar.sun.ac.za
107 
 
Another reason why our Coca Cola
®
 data may differ to the literature may be that animal 
studies using fructose typically use pure fructose as opposed to sucrose or HFCS, which is the 
primary source of fructose in humans. Rats are moderately resistant to fructose because they 
generate less uric acid (compared to humans) in response to fructose due to the presence of 
the uricase gene in their liver. Uricase degrades uric acid to allantoin, and as a consequence, 
rats degrade uric acid rapidly after it is formed in their liver. The metabolism of fructose in 
the liver leads to the formation of uric acid, which in turn increases the risk of developing IR 
and CVD. The mechanism appears to be mediated by uric acid–dependent intracellular and 
mitochondrial oxidative stress. Although uric acid is a potent antioxidant in the extracellular 
environment, when uric acid enters cells via specific organic anion transporters, it induces an 
oxidative stress that has been shown in vascular endothelial cells and adipocytes (Johnson et 
al., 2013). Further studies need to be conducted to calculate the actual fat percentage in the 
liver in order to draw meaningful conclusions from such findings. 
 
7.3.3.4 Visceral adipose tissue 
 
Although previous studies demonstrated an accumulation of visceral adiposity with SSB 
consumption (Anton et al., 2010; Malik et al., 2010; O’Keefe et al., 2008; Popkin, 2012), we 
did not find any meaningful changes. There were some changes but it was not significant 
versus both the controls here employed and therefore we propose that such changes cannot 
lead to reliable conclusions. However, the general lack of profound and consistent changes is 
consistent with our earlier findings that our experimental model represents early changes 
triggered by SSB consumption. It is thus likely that real changes in visceral adipose tissues 
may only be found with longer exposure to SSBs, i.e. beyond the six-months here employed.  
 
7.3.4 Adipose tissue analyses  
 
Abdominal obesity is a major risk factor for Diabetes and CVD. Excess visceral fat and 
subcutaneous adipose tissues are proposed to be key contributors to this process (Swarbrick 
et al., 2008). For example, several studies found that visceral fat and subcutaneous adipose 
tissues are associated with multiple cardiovascular risk factors as well as markers of 
inflammation and oxidative stress (Anton et al., 2010; Neeland et al., 2013). An insufficient 
subcutaneous adipose tissues reservoir for fat storage promotes ectopic redistribution of FAs 
to visceral adipose tissue, liver, and skeletal muscle, and predisposing individuals to 
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increased metabolic risks (Neeland et al., 2013). In light of this, we also measured the surface 
area of adipocytes isolated from the left visceral fat pads to assess whether this may be the 
case in our experimental model.  
 
Although the Coca Cola
®
 group did not show a significant difference in percentage visceral 
fat to body weight as discussed earlier, the adipocyte surface area was larger compared to the 
controls. This could be indicative that more FAs are converted to triglycerides for storage 
purposes (increasing adipocyte cell surface areas) (Zimmermann et al., 2004) and potentially 
placing the organism at risk for future CVD onset (Swarbrick et al., 2008). These results are 
in accordance with previous studies which show that SSBs is linked to excess visceral fat 
deposition (Anton et al., 2010; Popkin, 2012). For the Jive
®
 group a different scenario was 
found, i.e. although the overall area of the adipocytes were less than the controls, the total 
percentage of visceral fat to body weight appears to be increased. This leads us to speculate 
that there are numerous smaller adipocytes - this may also be as a result of excess FA 
deposition (Neeland et al., 2013) – that may also signal detrimental pathophysiologic 
outcomes. 
 
Together these findings (first part of this study) demonstrate that our rat model of chronic 
SSB/ASB consumption represents a relatively early stage during the progression towards the 
onset of cardio-metabolic complications. We found that there was no significant weight gain 
or profound changes in key circulating metabolites for any of the sodas employed. Moreover, 
food consumption remained unaffected for all groups studied while organ weight changes 
occurred only for some of the experimental groupings. These data therefore indicate that after 
six months there are limited visible macroscopic changes. However, our findings reveal that 
Jive
® 
consumption resulted in the most significant changes, with early evidence of cardiac 
and skeletal muscle hypertrophy together with increased liver weights. In addition, this group 
also displayed changes in adipocyte ultrastructure that could potentially have detrimental 
effects in the long-term. Interestingly, these changes were not found in the butter group that 





per se can elicit potentially damaging effects. The next stage of this study involves 
gaining some additional insights into putative underlying mechanisms that may be 
responsible for early changes triggered by SSB consumption.  
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7.4 Insulin resistance/Diabetes risk factors 
 
7.4.1 Oral glucose tolerance tests 
 
OGTTs were performed biweekly in order to evaluate the effects of SSBs, ASBs and butter 
on postprandial hyperglycemic excursions. Although both chronic and acute hyperglycemia 
has been linked with the development of CVD, we set out to investigate acute glycemic 
fluctuations as the literature falls short in this regard. Evidence suggests that acute 
hyperglycemia plays a vital role in the pathogenesis of developing vascular complications 
and has been linked with oxidative stress, endothelial dysfunction (Marcovecchio et al., 
2011) and increased acute myocardial infarction mortalities (Cao et al., 2005). Furthermore, 
repeated changes in postprandial excursions on a daily basis result in an increase in 
atherosclerotic risk factors and predisposition to coronary artery disease (O’Keefe et al., 
2008).  
 
The current study found that the different experimental groups exhibited significant variation 
in their respective OGTTs with the different time points here examined. These data suggest 
that SSB consumption triggers some effects that impact on insulin-mediated glucose uptake 
and metabolism. For example, we established that the Coca Cola
®
 and Coke Light
®
 groups 
displayed a much higher postprandial excursion (especially early on) after the six month time 
period. The butter group showed a similar result and these data suggest that in this instance 
there may be an impairment of insulin action on target cells and/or secretion by the pancreatic 
β–cells. Evidence shows that ASBs trigger the same insulin response as that of SSBs 
although with a diminished glycemic response (Anton et al., 2010). We were unfortunately 
unable to assess systemic insulin levels in our model (due to loss of sample materials) since 
this would have allowed us to calculate measures such as the homeostatic model assessment 





groups’ postprandial excursions were lower – again suggesting a problem 
with insulin-regulated glucose metabolism. This indicates that a greater insulin response was 
likely required as shown in the literature (Anton et al., 2010, Swithers, 2013) to reduce the 




groups, causing the blood glucose levels to 
decline significantly as found here. In support, Swarbrick et al. (2008) found that the 
consumption of fructose beverages over a period of ten weeks significantly increased the 
insulin response in humans and thus could predispose them to diminished insulin sensitivity 
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and lead to IR. Moreover, Popkin (2012) demonstrated that SSB consumption has adverse 
effects on insulin sensitivity, thus if this response is continually stimulated it could lead to the 
onset of IR.  
 
Anton et al. (2010) proposed that ASBs also trigger a higher glucose response than normal, 
although not as high as sucrose containing substances (SSBs). As noted, over the six month 
period we found lower blood glucose levels at three months and again an increase after six 
months. This could be indicative of impaired insulin response possibly leading to IR. These 
data correlate with the literature and add valuable information regarding ASBs and that it 
could also possibly lead to IR over an extended period of time. However, additional studies 
are required to gain a fuller understanding, e.g. insulin measurements in order to calculate the 
HOMA index, and an investigation of molecular markers of insulin-mediated glucose 
metabolism (heart, muscle, liver tissues). 
 
7.4.2 Non-oxidative glucose pathways 
 
We hypothesized that increased glucose availability (due to SSB consumption) will trigger an 
enhanced mitochondrial oxidative stress response, leading to upstream glycolytic metabolites 
being shunted into NOGPs, i.e. polyol, HBP, AGE, and PKC pathways.  
 
We found variable responses for the different NOGPs. Our data reveal that the Jive
® 
group 
displayed the most significant changes in terms of NOGP activation in the rat heart. Here we 
found that the HBP, PKC and polyol pathways were coordinately induced after three months, 
with the AGE pathway remaining essentially unchanged. This pattern continued and 
remained the same after six months, except the AGE pathway was now downregulated. For 
the other groups, the HBP also featured strongly, i.e. upregulated at either three and six 
month time points, or both. This suggests that the HBP is a relatively early and universal 
metabolic target that is triggered in response to chronic SSB and ASB consumption. For the 
remainder of the groups, we found that the PKC and polyol pathways were activated in 
punctuate fashion and sometimes up- or downregulated.   
 
Increased flux through the HBP has been implicated in glucose-induced insulin resistance. 
Glucosamine (an intermediate in the HBP) is several times more potent than glucose in 
inducing IR and reducing insulin responsiveness. The latter is a result of the modification of 
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gene transcription factors, via O-GlcNAcytion, relevant to glucose homeostasis/ insulin 
signaling (Buse et al., 2002; McClain and Crook, 1996). Several studies support this notion, 
e.g. GFAT (HBP rate-limiting enzyme) overexpression in mice develop IR with decreased 
muscle glucose disposal rates linked to reduced levels of the muscle-enriched glucose 
transporter, GLUT4 (Hebert et al. 1996). Similarly, skeletal muscle GFAT activity is 
significantly elevated in Type 2 diabetic patients (Rajamani et al., 2011; Yki-Jarvinen et al. 
1996). 
 
The collective activation of the NOGPs are also implicated in the onset of insulin resistance 
in heart cells and there is a strong interplay between such pathways (Joseph and Essop, 
2014). Thus we propose that activation of one or several of such pathways can further fuel 
activation of the NOGPs therefore creating a vicious metabolic cycle. Excessive NOGP 
activation can lead to more ROS production and also damaging downstream effects on the 
heart (Brownlee, 2005; Joseph et al., 2014; Mapanga et al., 2012). For example, we found 
that activation of NOGPs with ischemia-reperfusion (under acute hyperglycemic conditions) 
results in greater damage to hearts (Mapanga et al., 2012). Moreover, when these pathways 
were blunted our data reveal that hearts showed significantly improved functional recovery 
following ischemia-reperfusion. What are the upstream events that lead to NOGP activation? 
Oxidative stress is considered the linking mechanism whereby hyperglycemia mediates its 
activation of the NOGPs and with damaging effects (Brownlee, 2001). Here hyperglycemia-
induced ROS is thought to inhibit the glycolytic enzyme GAPDH, thereby increasing flux 
through upstream glycolytic metabolites into the NOGPs with downstream effects 
contributing to cardio-metabolic complications (Du et al., 2003). Therefore a possible 
mechanistic pathway may include oxidative stress as an initial downstream target of SSB 
consumption, followed by NOGP activation and the onset of pathophysiologic complications. 
We are currently in the process of investigating markers of oxidative stress in our model. It is 
also highly likely that other signaling pathways are also involved in SSB-mediated effects in 
our model and we are planning to perform proteomic analyses to gain more insights in this 
regard. 
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8.1 Summary of findings 
 
Obesity and CVD are becoming global pandemics, and even more so in developing nations. 
These diseases are associated with a sedentary lifestyle and unhealthy dietary habits. The 
molecular mechanisms underlying the etiology of such diseases are still not fully understood. 
We are of the opinion that a comprehensive understanding of the pathophysiological 
mechanisms driving the development of T2D and CVD is fundamental to curb the disease 
progression at an early stage. This thesis therefore evaluated the effects of SSB consumption 
(as part of the so-called Western diet) by establishing and characterizing a unique in vivo 
experimental model. Here the idea is to employ this model to gain novel mechanistic insights 
as to how SSBs can actually elicit cardio-metabolic complications in the long-term. We 
began by focusing on setting up the model and thereafter specifically focusing on whether 
NOGPs are activated in the myocardium.  
 
This study managed to successfully establish a novel in vivo rat model of chronic SSB/ASB 
consumption. Our data reveal that after six months the different soda groups display minimal 
macroscopic changes, therefore representing a relatively early stage in terms of SSB-
mediated cardio-metabolic complications. However, we found several changes at the 
biochemical level but with distinct signatures for the Jive
®
 group compared to the Coca 
Cola
®
 and Coke Light
®
 groups. Here Jive
®
 consumption for six months resulted in early signs 
of cardiac and skeletal muscle hypertrophy, together with increased liver mass and perturbed 
adipocyte ultrastructure. We also established that the majority of the myocardial NOGPs 
were activated which may have contributed to some of the changes already found and could 
also lead to future complications. The Coca Cola
®
 and Coke Light
®
 groups exhibited 
alterations in liver mass and altered adipocyte ultrastructure together with lower glucose 
clearance after six months suggesting onset of IR. The HBP also emerged as a universal 
pathway that was activated in all of the soda groups and may thus represent a useful 
therapeutic target within this particular context. Therefore, our study alerts to potential side-
effects of long-term SSB intake that may place organisms at risk of developing cardio-
metabolic complications despite an apparently “healthy” phenotype. 






We were unable to assess systemic insulin levels in our model (due to loss of sample 
materials) since this would have allowed us to calculate measures such as the HOMA to gain 
insight regarding insulin sensitivity. Blood serum availability was limited and thus only a few 
systemic metabolites could be evaluated. Due to time constraints we were unable to assess 
oxidative stress markers and/or anti-oxidant modulators.  
 
8.3 Future direction 
 
For future studies we plan to further evaluate The following: a) ex vivo heart perfusions to 
determine SSB effects on heart function, b) blood pressure assessments, c) endothelial 
functional analyses, d) oxidative stress markers, e) mitochondrial respiration studies, f) a 
comprehensive analysis of signaling pathways (cell death, hypertrophy, insulin/glucose 
metabolism) and g) histological analyses of different tissues (heart, pancreas, muscle, liver). 
 
The damaging downstream effects of the NOGPs also need to be measured, e.g. 
inflammatory markers such as NFκB as well as NO levels to determine vasodilation 
capabilities. Future studies are also necessary to pursue reasons behind the continual 
activation of the HBP. Finally, this experimental system will be replicated in an obese model 
to simulate the effects of SSB consumption in a person already predisposed to cardio-
metabolic complications. Such collective investigations should thus significantly contribute 
to an improved mechanistic understanding of the damaging effects of SSB consumption and 
its link to T2D and CVD. 
 
  











Protein extraction from tissues 
 
Preparation of RIPA buffer  
Base ingredients 
 Tris-HCl (buffering agent prevents protein denaturation) 
 NaCl (salt prevents non-specific protein aggregation)  
 NP-40 (non-ionic detergent to extract proteins; 10% stock solution in H2O) or use 
Triton X-100 
 Na-deoxycholate (ionic detergent to extract proteins; 10% stock solution in H2O; 
protect from light). Adjust the pH to 9, then boil, cool, and re-adjust the pH to 9. 
Repeat this process until the solution becomes colorless 
 
Note: Do not add Na-deoxycholate when preparing lysates for kinase assays. Ionic detergents 
can denature enzymes, causing it to lose its activity.  
 
RIPA protease inhibitors 
 Phenylmethylsulfonyl fluoride (PMSF) (200 mM stock solution in isopropanol; 
store at room temperature) 
 EDTA (calcium chelator; 100 mM stock solution in H2O, pH 7.4) 
 Leupeptin (store frozen in aliquots, 1 mg/ml in H2O) 
 Aprotinin (store frozen in aliquots, 1 mg/ml in H2O) 
 Pepstatin (store frozen in aliquots, 1 mg/ml in methanol) 
 
 
RIPA phosphatase inhibitors 
 Activated Na3VO4 (200 mM stock solution in H2O; see sodium orthovanadate 
activation protocol). 
 NaF (200 mM stock solution: store at room temperature) 
Note: Do not add phosphatase inhibitors when preparing lysates for phosphatase assays. 
 
 




 RIPA trypsin inhibitors 
 Soyabean Trypsin Inhibitor (SBTI) (1 mg/ml in 0.01 M phosphate buffer, pH 6.5 
with 0.15 M NaCl- freeze aliquots at -20ºC) 
 Benzamidine (200 mM stock solution -dissolve in ddH2O – store at -20ºC) 
 
Sodium orthovanadate activation protocol 
1. Sodium orthovanadate should be activated for maximal inhibition of protein 
phosphotyrosyl-phosphatases. 
2. Prepare a 200 mM solution of sodium orthovanadate. 
3. Adjust the pH to 10 using either 1 N NaOH or 1 N HCl. The starting pH of the 
sodium orthovanadate solution may vary depending on different lots of the 
chemical. The solution will become yellow in color at pH 10. 
4. Boil the solution until it turns colorless (~ 10 minutes). 
5. Cool to room temperature. 
6. Re-adjust the pH to 10 and repeat steps 3 and 4 until the solution remains 
colorless and the pH stabilizes at 10. 
7. Store the activated sodium orthovanadate as aliquots at -20°C. 
8. This procedure de-polymerizes the vanadate, converting it into a more potent 
inhibitor of protein tyrosine phosphatases. 
 
Procedure:  
Prepare 100 ml modified RIPA buffer as follows:  
 Add 790 mg Tris base to 75 ml distilled water (ddH2O). Then add 900 mg NaCl and 
stir the solution until all solids are dissolved. Using HCl, adjust the pH to 7.4. 
 Add 10 ml of 10% NP-40 to the solution. 
 Add 2.5 ml of 10% Na-deoxycholate and stir until solution is clear. 
 Add 1 ml of 100 mM EDTA to the solution. Adjust the volume of the solution to 100 
ml using a graduated cylinder.  
 Ideally, the remaining protease and phosphatase inhibitors should be added to the 
solution on the same day for running of the assay. Therefore, it is best to aliquot the 
buffer in 10 ml aliquots without the protease inhibitors and store at 2-8°C. 
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 RIPA with inhibitors - on day of use, thaw the required amount of RIPA buffer and add 
the appropriate volume of protease inhibitors to the buffer. 
For 10 ml RIPA add: 
 
10 μL aprotonin; 10 µL of leupeptin; 50 µL of PMSF, Na3VO4, and NaF and benzamidine, 
100 μL pepstatin and 50 µL Pugnac. 
  
NB: these are the volumes for 10 ml of RIPA, but with the exception of PMSF, the diluted 
inhibitors are stable in aqueous solution for up to 5 days. 
  
The final concentrations in the modified RIPA buffer should be:  
 
Tris-HCl: 50 mM, pH 7.4 
NP-40: 1% 
Na-deoxycholate: 0.25% 
NaCl: 150 mM 
EDTA: 1 mM 
PMSF: 1 mM 
Leupeptin, benzamidine: 1 µg/ml each 
Aprotonin: 1 ug/ml 
Pepstatin: 10 ug/ml 
Na3VO4: 1 mM 






 Cut tissue samples into small pieces and place into a 2 ml microtube. 
 Pour RIPA buffer into the microtubes containing the tiny pieces of tissue samples – 
(aim to make homogenates that are 1:2 w/v tissue: lysis buffer). 
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 Using a dounce homogenizer (Ultra-Turrax homogenizer, IKA, China), homogenize 
the tissue until a fine slurry is obtained; then sonicate (Misonixa ultrasonic liquid 
processor S-4000, Hielscher, Germany) each sample for 10 seconds at 4 amps. 
 Transfer the homogenates to fresh pre-chilled 2 ml microtubes and keep on ice. 
 Once the foam has dissipated (1 hour) collect the content of the microtube and 
transfer it into a clean tube. 
 Centrifuge (Spectrafuge™ 24D, Labnet, Edison NJ) at 17 226 x g. for 15 minutes at 
4ºC. 
 Transfer the supernatants (protein lysates) to clean pre-chilled microtubes. 









Bradford protein determination 
 
Stock solution 5 X concentration: 
 Dilute 500mg Coomassie Brilliant blue G250 in 250 ml 95% ethanol. 
 Add 500 ml phosphoric acid, mix thoroughly. 
 Adjust the volume to 1 L with ddH2O. 
 Filter solution and store at 4ºC. 
Working solution 
 Dilute stock solution in a 1:5 ratio (100 ml:500 ml) with ddH2O. 
 Filter with two filter papers (Munktell, filter paper, 3HW 240 mm, Sweden). 
 The filtered working solution should be a light brown color and is light sensitive. 
 
Method 
 Thaw the 1 mg/ml BSA stock solution. 
 Dilute the BSA stock solution to a final concentration of 200 µg/ml (100 µL of 1 
mg/ml stock + 400 µl ddH2O). 
 Thaw the lysate samples on ice (if frozen) and keep on ice at all times. 
 Mark 2 ml microtubes, i.e. n=14 for the standards (each standard in duplicate) and 
n=2  for each sample (also done in duplicate). 



















                                                                                                                   
BSA ddH2O Concentration 
0 100 µL Blank 
10 µL 90 µL 2 µg 
20 µL 80 µL 4 µg 
40 µL 60 µL 8 µg 
60 µL 40 µL 12 µg 
80 µL 20 µL 16 µg 
100 µL 0 µL 20 µg 
 
 For the samples, place 95 µL of ddH2O into each sample tube and add 5 µL of protein 
sample to appropriately labeled tubes (in duplicate). 
 Vortex (Scientific industries, Bohemia NY) all tubes briefly. 
 Add 900 µL Bradford working solution to each tube and vortex again. 
 Incubate tubes at room temp for at least 5 minutes (reaction is stable for up to 60 
minutes). 
 Switch on the spectrophotometer (Cecil CE 2021, 2000 series, Cambridge) and allow 
it to warm up for calibration, then set wavelength to 595 nm. 
 Read the absorbance of both the standards and all experimental samples. 
 If the absorbance of samples falls outside the range of the highest standard, dilute 
with RIPA buffer and read again – remember to multiply result by dilution. 
 Use the Bradford graph program to obtain a standard curve and unknown protein 
values (in µg). 
 Prepare samples with the loading buffer (1:1 ratio). 
  
Standard curve preparation required to determine protein concentrations. 





Protocols: Western blotting 
 
SAMPLE PREPARATION: 
Laemmli’s loading buffer 
ddH20 3.8 ml 
0.5 M Tris-HCl, pH 6.8 1.0 ml 
Glycerol 0.8 ml 
10% (w/v) SDS 1.6 ml 
0.05% (w/v) Bromophenol blue 0.4 ml 
 
Materials: 
1.5 ml microtubes 
Sharp tweezers or a syringe needle 
β-mercaptoethanol 
Ice 
Heating block set to 95
ο
C (or beaker of water on hot plate) 
Vortex (Scientific industries, Bohemia NY) 
Microtube centrifuge (Spectrafuge
™
 24D, Labnet, Edison NJ)  
 
Protocol: 
Make a working solution of Laemmli’s sample buffer – 850 µL Laemmli’s stock buffer 
solution together with 150 µL β-mercaptoethanol (work in fume hood). Vortex (Scientific 
industries, Bohemia NY) thoroughly. 
 
Calculate the appropriate volume of each sample to give equal loading protein amounts (e.g.: 
50 μg protein/sample) and calculate the number of sample sets needed. 
 
Label microtubes for each sample. 
 
Add the appropriate amount of working solution of Laemmli’s and RIPA buffer, as 
calculated, to each appropriate tube (work in fume hood). 




Add the appropriate volume of each protein sample to respective microtubes. 
 
Close samples and punch small hole in lid with tweezers or syringe needle. 
 
Heat samples on heating block for 5 minutes. 
 
Centrifuge (Spectrafuge 24D Labnet, Edison NJ) each tube at 17, 226 x g (briefly for 10 
seconds) and place on ice immediately. 
 
Samples can now either be stored at -20
ο
C for future use or directly loaded onto gels. 
 
Gels: 




 Gels, 4-20%, 10 well combs, 
50 µL with stain-free enabled imagers, Hercules CA) were used for all HBP analyses (see 
details below). 
 
1: Add 7.5 µL of protein marker (BIO-RAD, unstained Precision Plus Protein
™
 standard, 
Hercules CA) to the first lane on the far left of each precast gel (BIO-RAD, Hercules CA). 
 
2: Add the appropriate amount (calculated from Bradford protein quantification) of sample 
slowly into respective lanes using the gel-loading tips. 
 
3: Place the green lid with appropriate leads (black to black: red to red) on top of the tank and 
connect to the power pack (Power PAC 1000, BIO-RAD, Hercules CA). 
 
4. Add running buffer to just below the line indicated on the tank. 
Running buffer: 10x SDS (1L) 
 10 grams SDS 
 30.3 grams Tris-base 
 144.1 grams glycine 
Dissolve in 800.ml ddH2O, adjust volume to 2 L. Make 1x running buffer by adding 100 ml 
10x running buffer to 900 ml ddH2O. 




5: Run at 300V (constant), 400 mA for 15-20 minutes to allow samples to migrate through 
gel. 
 
6: Switch off power and disconnect electrodes. Remove gel plates from the tank and 
immediately proceed to the electro-transfer step. 
 
7: Image gels to evaluate sample migration as well as visualizing total protein content of each 
sample (Image Lab
™
 Software version 4.0, BIO-RAD, Hercules CA). 
 
Transfer using Transfer Turbo and Chemi-Doc: 
 




, transfer pack, BIO-RAD, mini format, 0.2 μm 
PVDF, single application, Hercules CA) and place the blotting paper marked “bottom” on 




, transfer system, BIO-RAD, Hercules CA) 
cassette on top. Gently roll out any air bubbles. Place the gel on top of the membrane with the 
low molecular weight protein side facing towards the center of the cassette and again gently 
roll out any trapped air bubbles. Then place the blotting paper marked “top” from the transfer 
pack over the gel and roll out air bubbles (align the blotting paper tabs in the same manner as 
when it came out of the transfer pack). 
 
 Place lid on top and lock in place. 
 
 Place the cassette in the Transfer Blot (Trans-Blot® Turbo™, transfer system, BIO-
RAD, Hercules CA ) and set to transfer for 7 minutes, this will allow the protein to be 
transferred from the gel onto the membrane. 
 
 Check that protein has transferred and then place in methanol for 30 seconds then 
leave to dry completely. 
 
 Rinse membrane 3 x 5 minutes with TBS-T. 
 
10x TBS Buffer: 
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 48.4 grams Tris 
 160 grams NaCl 
Dissolve in 1.5 L ddH2O. Set pH to 7.6 with HCl and adjust volume to 2 L. 
1x TBS-T buffer: 
 100 ml 10x TBS buffer 
 900 ml ddH2O 
 1 ml Tween 
 
 Block for 15 minutes in 5% BSA – made up in TBS-T (5 grams BSA 100 ml TBS-T). 
 
 Wash 3 x 5 minutes in TBS-T. 
 
 Place membrane in 50 ml Falcon tube (BD Bioscience, Bedford MA) containing 5 ml 
of primary antibody – a 1/1000 dilution of the O-GlcNAc IGg mouse monoclonal 
primary antibody (CTD110.6, Santa Cruz Biotechnology, Santa Cruz CA) was used.  
 Place on rotator in 4ºC walk-in fridge overnight. 
 
DAY 2: 
1:Remove membrane from primary antibody (save antibody – freeze at -20ºC). 
2:Wash 3 x 5 minutes in TBS-T. 
3: Prepare secondary antibodies by diluting in 5 ml TBS-T in a 50 ml Falcon tube (BD 
Bioscience, Bedford MA). A 1:1000 dilution was used (5 µl secondary antibody in 5 
ml TBS-T). An anti-mouse monoclonal secondary antibody (anti-mouse IgG, HRP-
linked, Cell Signaling Technology
®
, Danvers MA) was employed and placed on roller 
for 1 hour at room temperature. 
4:Pour off secondary antibody into tube and freeze for later use. 
5:Wash membrane 3 x 5 minutes in TBS-T. 
6: Take ECL reagents (BIO-RAD, Hercules CA) A & B from fridge and equilibrate to 
room temperature. 
7: Prepare ECL substrate in a 1:1 ratio of A:B. Use foil-covered microtubes to prepare 
solution as ECL is light sensitive. 
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8: Pour off the TBS-T from membrane and add ECL, spreading evenly over the surface 
of the membrane by gentle tilting. If MW of protein is known, just add ECL to this 
area to save on the amount of ECL as it is very costly. 
9:Swirl gently for 2 minutes. 
10: Place membrane on tray of  the ChemiDoc (BIO-RAD, ChemiDoc
™
, XRS+ system, 
Hercules CA) taking care to remove any visible bubbles. 
 
Image analysis on Chemi-Doc: 
1. Select “Image Lab™ Software version 4.0 (BIO-RAD, Hercules CA), quantification 
analysis” program from desktop on computer. 
 
2. The ‘’start’’ page will pop up – can choose an existing protocol or create a new one. 
 
3. All protocol settings can be modified by selecting the item on the left under “Protocol 
Set Up”. 
 
4. For self-poured gels: Select “Blot” and then select “Chemi” from drop-down window. 
 
5. Next, set the imaging area to 12 x 9 cm (W x L). 
 
6. Specify the optimum exposure e.g. “intense bands”.  
 
7. Default color is auto selected – you can change this if required. 
 
8. Select “Lane and Band Detection”. 
 
9. Select either “Low” or “High” for intense or faint bands or use the “custom” slider to 
set exact sensitivity. 
 
10. Select “Analyze MW” then select MW standard used, the appropriate lane and the 
regression method (linear, semi-log) - if using Bio-Rad marker you can analyze 
against this (a stain-free marker was used in order to activate and visualize total 
protein content before the gel was transferred to the membrane). The stain-free gel 
does not require a loading control as the total protein content is visualized and 
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analysed for normalization. Gels are visualized to calculate total protein content 
(Image Lab
™
 Software version 4.0, BIO-RAD, Hercules CA) 
 
11. Generate a report: Specific output, then provide a customized name and specify 
whether to be printed or displayed. 
 
12. Save the protocol summary.  
 
13. Load the gel into the imager and position it on the stage using the “position gel” 
option – this will produce a live image of the gel’s position –adjust by opening the top 
door of Chemi-doc- adjust the zoom settings and position to obtain image exactly as 
required. 
 
14. When gel is correctly positioned, click on “Run Protocol”. 
 
15. Once protocol has run, the images and report will be displayed with all selected 
analyses applied. 
 
16. Save the images required to an appropriate folder in ‘’Documents’’. 
 









H &E Staining  
 
Hemalum colors the nuclei of cells blue. The nuclear staining is followed by counterstaining 
with an aqueous solution of eosin Y, which colors other structures in various shades of red 
and pink (Avwioro, 2011). 
 
Procedure:  
   
1.    De-paraffinize sections, 2 changes of xylene, 5 minutes each.  
 
2.    Re-hydrate in 2 changes of absolute alcohol, 5 minutes each. 
  
3.    95% alcohol for 2 minutes and 70% alcohol for 2 minutes.  
 
4.    Wash briefly in distilled water, (if frozen section – start here). 
 
5.    Stain in Mayer hematoxylin solution for 8 minutes.  
 
6.    Wash in warm tap water for 10 minutes (place tap water in oven before the start of the 
stain). 
  
7.    Rinse in distilled water. 
  
8.    Rinse in 95% alcohol, 10 dips. 
  
9.    Counterstain with eosin-phloxine B solution (or eosin Y solution) for 30 seconds (50% 
ddH2O to eosin). 
 
10.  Dehydrate through 95% alcohol, 2 changes of absolute alcohol, 5 minutes each (mount 
frozen sections here here). 
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11.  Clear in 2 changes of xylene, 5 minutes each.  
 
12.  Mount with xylene-based mounting medium.  
 
   
Results:  
   
Nuclei --------------------------------------- blue  









1. Avwioro, G. (2011). Histochemical uses of haematoxylin—a review. J Pharm Clin 
Sci (JPCS), 1, 24–34.  
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